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CHAPTER 1 INTRODUCTION 
1.1. Anti-cancer activities of piperlongumine (PL) 
 
Figure 1. a) Pictures of long pepper, and PL was originally extracted from this 
plant. b) Chemical structure of PL. 
 
The dried long pepper is usually used as a seasoning in Indian and 
Malaysian cuisine. Labeled with pippali, long pepper is readily available in many 
Indian grocery stores. Today, there are growing interest on Piperlongumine (PL), 
an alkaloid identified from the long pepper. PL was originally isolated from the root 
of Piper longum L (Figure 1a), and its structure and synthesis was elaborated in 
19671 (Figure 1b). PL has multiple pharmacological activities2, including 
anti-tumor, anti-depressant, anti-diabetic, anti-bacterial, anti-platelet aggregation, 
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etc. Among them, anti-cancer activities are very attractive, as demonstrated in a 
nature paper published in 20103. As shown in Figure 2, PL affects various 
oncogenic pathways in multiple cancer cells, covalent protein modifications and 
induction of reactive oxygen species (ROS) are believed to be the key mediators 
of the observed anti-cancer effects4. 
 
Figure 2. PL modules multiple oncogenic pathways and was studied in various 
cancer models, including prostate5,6,7, melanoma8, lung9, breast10, colon11, 
leukemia12,13,14,15, pancreatic16, oral17, bladder18, gastric19 and renal cancer20.  
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1.1.1. PL is an anti-cancer electrophile 
 
Figure 3. Structure-activity relationship and mechanisms of action of PL against 
cancer cells. Two Michael acceptors contribute to the overall anti-cancer activities. 
C2-C3 olefin correlates with ROS elevation, and C7-C8 enhances cytotoxicity. PL 
covalently interacts with cellular thiols such as GSH, GST, Keap1, TrxR, IKK, 
p65/p50(NF- NF-κB), etc. Abbreviations: GSH: glutathione; GST: glutathione 
S-transferase; Keap1: Kelch-like ECH-associated protein 1; TrxR: thioredoxin 
reductase; IKK: IκB kinase; p65/p50: two subunits of NF-κB transcriptional 
complex. 
 
Anti-cancer activities of PL heavily rely on the unique electrophilic property. 
PL consists of two α, β-unsaturated moieties (C2-C3 and C7-C8 olefins) known as 
"Michael-acceptors," thereby harboring electrophilicity. The functionality of C2-C3 
olefin and C7-C8 olefin is associated with GSH conjugation and glutathionylation 
of GSH-binding proteins21, respectively (Figure 3a). Besides GSH-binding 
proteins, PL can also covalently modify other cellular proteins such as IKK22, 
p65/p50 (NF-κB)23 and Keap124 (Figure 3b). Current research points out that 
chlorine introduction at C2 of PL notably enhances PL's electrophilicity, thereby 
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leading to more potent anti-cancer activities25,26. C7-C8 olefin is primarily shown 
to increase protein glutathionylation, and its removal causes significant reductions 
in cytotoxicity21. Other modifications on either the trimethoxy group or the 
aromatic ring barely affect the potency of PL in cancer cells21,25, demonstrating the 
tolerability and feasibility of PL structural modifications. In conclusion, C2-C3 and 
C7-C8 olefins are the most critical determinants for PL's actions, and 
modifications on other positions distal from these olefins are tolerable. Therefore, 
PL is a suitable research tool due to its favorable electrophilicity, and much effort 
has been continuously placed to explore the electrophilicity-based prooxidant 
anti-cancer strategy due to the intrinsic relationship between electrophilicity and 
oxidative stress21. 
The chemical reactivity of α,β-unsaturated carbonyl group of electrophiles 
decides PL's electrophilicity. Given the relatively reactive chemical property, 
α,β-unsaturated double bond of electrophiles generally reacts with many 
nucleophiles via Michael addition, including the amine group of Lys, the imidazole 
group of His, and the thiol group of Cys27. Among them, the reaction of 
electrophiles with Cys thiol is more readily and stable, especially the reaction with 
a more nucleophilic thiolate formed through deprotonation when Cys is located in 
basic environment or proximity to positively charged amino acids27. GSH is the 
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abundant source of cellular thiols and participates in antioxidant defense, so 
electrophiles are inevitable to react and consume intracellular GSH, thereby 
increasing oxidative stress28. In addition to antioxidant GSH depletion, they also 
covalently inhibit thiol-containing proteins (e.g., GST, TrxR, GCLC, GPX1 etc.) 
involved in the antioxidant defense system, attenuating ROS scavenging12, 29. 
Therefore, electrophilicity of electrophiles connects with oxidative stress through 
interfering with antioxidants or antioxidant defense systems. 
1.1.2. Anti-leukemic activities of PL 
PL reduced the viability of various AML cell lines (e.g., U937, MV4-11, etc.) 
with the IC50s in low micromolar range (1-3 μM)
30, and was also effective in 
inhibiting CD34+ AML stem cells through targeting glutathione metabolism12. PL 
induced apoptosis and autophagy in AML patient samples, as evidenced by the 
upregulation of Bax, Bcl-2, caspase-3, Becline-1, LC3B, p-p38, and p-JNK31. 
In addition to AML, PL inhibited the growth of B-cell acute lymphoblastic 
leukemia cell line through several mechanisms, including downregulation of 
multiple transcriptional factors (eg., AP1, MYC, NF-κB, Sp1, STAT1, STAT3, E2F1, 
etc.), p21 upregulation independent of p53, and ROS elevation13. Also, PL 
displayed anti-acute promyelocytic leukemic (APL) activities through inhibition of 
COX-2 and induction of caspase-3 cleavage14. PL was able to reverse drug 
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resistance of CML K562/A02 cells by reducing P-gp, MDR1, and MRP expression, 
and decreasing AKT phosphorylation as well as NF-κB transcriptional activity15. 
Moreover, p53 and p27 upregulation was observed in the same cell line following 
PL treatment15. 
1.1.3. Anti-prostate cancer activities of PL 
PL exhibits diverse bioactivities against prostate cancer (PCa): 1) PL 
inhibited AR-positive LNCaP proliferation at low micromolar concentrations 
(IC50<5uM) and effectively depletes full-length AR and AR variants through 
proteasome-mediated ROS-dependent mechanism5. 2) PL decreased 
phosphorylation of AKT at both S473 and T308 sites and downstream mTORC1 
activity, thus promoting autophagy in AR-negative PC-3 cells6. 3) PL 
downregulated NF-κB signaling independently of AKT, leading to diminished 
adhesion and invasion of prostate cancer cells7. Besides these anti-prostate 
cancer mechanisms, PL also displays pleiotropic activities in other types of cancer 
through affecting JNK-EKR signaling pathway32, GST Pi 1 activity33, p38-JNK31, 
TrxR1 activity19, ubiquitin-proteasome system34, and an array of transcriptional 
factors including c-Myc and Sp1, Sp3 and Sp435 (Figure 2). On the other hand, 
since PL serves as a versatile anti-cancer compound, it has been further 
combined with other chemotherapeutic agents such as cisplatin or paclitaxel36, 
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auranofin37, TRAIL38, and SAHA30. 
1.2. Acute myeloid leukemia (AML) 
Acute myeloid leukemia (AML) occurs in bone marrow and blood with the 
rapid growth of uncontrolled immature myeloid blast cells. AML is characterized 
by genetic heterogeneity and malignant clonal disorder of the hematopoietic 
system. Historically, the first report about AML was published by a Scottish 
physician, Peter Cullen, who described an unknown "milky blood" symptom in 
181139. In 1847, Rudolph Virchow named this disease "Leukemia"40. AML is one 
type of leukemia and is a highly acute and fatal malignancy. AML patients without 
treatments will typically die within six months or less41. 40 years ago, the overall 
survival of AML was less than 7%42. To date, breakthroughs in cytogenetic and 
hematopathologic advances lead to the significantly improved survival rate of AML 
to 35%-40% for adult patients43, and 60%-70% for children patients44. However, 
although such efforts have been made to increase patient's survival, the overall 
remission rate of AML is still less than 50% for patients younger than 60 years old, 
and only 5-15% for patients older than 60 years old45. AML patients are often 
accompanied by several symptoms in a wide range, including pancytopenia, 
anemia, pale, fatigue, thrombocytopenia, sweet syndrome, blast proliferation, 
hyperleukocytosis, CNS infiltration, and intravascular coagulation, etc46. In 2015, 
8 
 
AML was affecting nearly 1 million people and was reported to be the most 
prevalent leukemia type among four types of leukemia ( total 2.3 million patients 
with leukemia) in the world47. The current treatments for AML have not been 
changed dramatically over 30 years and mainly rely on chemotherapy and 
hematopoietic stem cell transplantation (HSCT)43, while these treatments have 
limitations considering patient tolerance, AML fast relapse, and potential resistant 
occurrence. 
1.2.1. Epidemiology 
In the USA, estimated 62,130 cases were expected to be diagnosed with 
leukemia in 2017, which increased 19% than that in 201448,49. The percentage of 
populations with AML accounted for 34-36% in total cases with leukemia in 
2014-201748,49. AML was the most common leukemia type among four types of 
leukemia and was also the fatal leukemia type, with the highest mortality (43% of 
all leukemia-causing deaths) and lowest overall 5-year survival rate. ( 26.8% of 
AML vs 65.9% CML vs 85.1% CLL vs 70.7% ALL)48,49. In gender, men were seen 
leukemia more common than women in 2017, with around 40.2 percent higher 
death rate for men than women49. Similar to the general gender trend, AML had 
27% higher occurrence rate in men (estimated 11,960 cases) than women (9,420 
cases) according to the 2017 statistics49. In race and ethnicity, AML was more 
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common in whites (85.6%) than in blacks (14.4%), as shown in 2016 report50. At 
age, people were usually diagnosed with AML within the age range from 65-74. 
The percentage of patients who die from AML was highest within the age of 
75-8451. 
1.2.2. Pathogenesis 
Multiple characteristics present in AML patients have been identified by 
using genome sequencing, flow cytometry, conventional cytogenetic testing, and 
genetic lesion screening. According to the latest revision of WHO classification of 
tumors of hematopoietic and lymphoid tissues in 201652, the major focus is on 
cytogenetic and molecular genetic abnormalities. These genetic abnormalities 
and molecular lesion are commonly detected and believed to drive the occurrence 
of AML. 
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Figure 4. Cytogenetic abnormalities in AML. Abbreviations: PML-RARα: 
promyelocytic leukemia-retinoic acid receptor alpha fusion; RUNX1: Runt-related 
transcription factor 1; CEBPA: CCAAT/enhancer-binding protein alpha; DNMT3A: 
DNA (cytosine-5)-methyltransferase 3A; TET2: Tet methylcytosine dioxygenase 2; 
IDH1: IDH1/2: isocitrate dehydrogenase 1/2; FLT3: fms-like tyrosine kinase 3; KIT: 
mast/stem cell growth factor receptor; KRAS/NRAS: two members of RAS protein 
family; TP53: tumor suppressor p53 gene; WT1: WT1: Wilms' tumor suppressor 
gene; NPM1: nucleophosmin. 
 
With many gene mutations revealed, not a single gene mutation accounts for AML 
pathogenesis. In normal hematopoiesis, the myeloblast cells can grow into mature 
white blood cells, however, they undergo differentiation arrest caused by genetic 
changes (e.g., production of a PML-PARα fusion protein) in AML53. This arrest, 
along with other gene disruption controlling cell proliferation, will result in 
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uncontrolled growth of immature myeloblasts and eventually lead to clinic entity 
and following clinical manifestations of AML. The percentage of blasts is important 
for the diagnosis of AML, with at least 20% myeloid blasts found in bone marrow 
and/or peripheral blood46. Cytogenetic abnormalities in AML can be classified into 
seven subsets54,55,56,43,57: 1) transcription factor fusion (PML-RARα, RUNX1, and 
CEBPA); 2) NPM1 encoding gene; 3) tumor-suppressor genes (TP53 and WT1); 4) 
genes encoding epigenetic modulation (DNMT3A, TET2, IDH1, and IDH2); 5) 
activated signaling pathway genes (FLT3, KIT, and KRAS/NRAS); 6) 
cohesion-complex genes; 7) spliceosome-complex genes. Regarding cellular 
effects, these gene mutations could also be mainly divided into three classes. 
Gene mutations in Class I affect cellular signal transduction such as FLT3, KIT, 
NRAS, KRAS, JAK2, and PTPN11; Class II disrupts cell differentiation, including 
RUNX1(AML-1), MLL, RARα, CBFβ, NPM1, etc. Class III includes TET2, IDH1 or 
IDH2, DNMT3A, EZH2, etc., and interferes with epigenetic modification. Other 
class includes WT1 and TP53, affecting tumor suppression58,59. Class I and class 
II are complicated and intertwined for initiation of AML, either class I or class II 
doesn't guarantee hematogenesis. For example, Dr. Gilliland group reported that 
FLT-ITD (Class I) could induce myeloporliferative disorder while not sufficient to 
initiate observed AML phenotype in humans, suggesting the necessary 
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participation of additional cooperative mutations60. Following the previous study, 
the same group demonstrated that Class II PML-RARα and FLT-ITD could 
cooperatively induce acute promyelocytic leukemia (APL) in the mouse model61. 
Different from class I and class II gene mutations, class III recurrent somatic 
mutations identified from genome-wide and candidate-gene studies are found to 
be a common genetic event in AML patients. They contribute to the pathogenesis 
of myeloid malignancies though regulating DNA methylation (e.g., TET2, 
DNMT3A) and histone post-modification (e.g., MLL, PRC)62. 
 
Figure 5. Genetic abnormalities and non-genetic aberrations contribute to the 
leukemogenesis of AML. 
 
In addition to genetic aberrations, non-genetic alterations also play an 
important role in leukemogenesis. For instance, miR-125 is overexpressed in AML 
patient blasts and promotes the transformation of normal hematopoietic cells to 
AML63; Cytokine (IL-3) stimulation or PML-RARα alone only leads to limited 
effects on myelopoiesis, while IL-3 combined with PML-RARα can lead to fatal 
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diseases with AML phenotypes, suggesting the cooperation of cytokine with gene 
abnormalities in leukemogenesis64; Heightened endogenous ROS sustained by 
leukemic cells exacerbates oxidative damage, thereby leading to advantageous 
DNA mutation which promotes leukemogenesis65. Therefore, genetic 
abnormalities involving gene mutations and non-genetic changes (e.g., miRNA, 
cytokine, and redox dysregulation) are critical for leukemogenesis. 
1.2.3. Potential therapeutic targets and treatments 
In general, with the development of leukemic biology and molecular 
pathology, AML therapies are widely available and optimizing toward patient 
individualization. These therapies mainly contain intensive chemotherapy and 
allogeneic hematopoietic stem cell transplantation. Much effort has been made 
into the discovery of "targeted agents", development of novel drug combination 
and optimization of safer stem cell transplantation procedures. However, current 
AML management still heavily relies on chemotherapy in younger adult patients 
(<60 years of age). There are not effective agents available for older patients (>60 
years of age) or patients unable to tolerate chemotherapy66. In this context, novel 
drugs or antibodies are discovered and developed by targeting a variety of cellular 
oncogenic signaling pathways, epigenetic modifications, antigens presenting on 
leukemic cells or leukemic stem cells, etc. These new drugs either approved by 
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FDA or under preclinical or clinical trials are summarized in the following table45, 
and their potential targets are also shown. 
Table 1 Drugs targets and therapeutic agents for the treatment of AML. The table 
was adapted from Dohner 201545. 
Potential 
Targets/Action 
Mechanism 
Agents Clinical Status Clinical Trials 
Conventional drugs    
 Cytarabine 
FDA approved 
in 1969 
 
 Daunorubicin 
FDA approved 
in 1979 
 
 Arsenic Trioxide 
FDA approved 
in 2000 
 
Epigenetic modifiers    
Hypomethylating 
agents 
Decitabine Phase IV NCT03026842 
 Azacitidine Phase IV NCT01806116 
 Oral azacitidine Phase III NCT01757535 
IDH1 inhibitor AG-120 Phase III NCT03173248 
IDH2 inhibitor AG-221 Phase III NCT02577406 
DOT1L inhibitor EPZ-5676 Phase I NCT02141828 
Bromodomain inhibitor OTX015 Phase I NCT01713582 
LSD1 GSK2879552 Phase I NCT02177812 
Histone deacetylase 
inhibitors 
Vorinostat Phase III NCT01802333 
 Panobinostat Phase II NCT00880269 
 Valproic acid Phase I/II NCT01369368 
Tyrosine kinase 
inhibitors 
   
FLT3 inhibitors Midostaurin Phase III NCT03379727 
 Sunitinib Phase I/II NCT00783653 
 Sorafenib Phase II/III NCT02474290 
KIT inhibitors Dasatinib Phase III NCT02013648 
 Midostaurin Phase III NCT03379727 
Cell--cycle and    
15 
 
signaling inhibitors 
MDM2 inhibitor Idasanutlin Phase III NCT02545283 
PLK inhibitor Volasertib Phase IV NCT01721876 
Aurora kinase inhibitor Barasertib Phase I/II NCT03217838 
CDK inhibitor Alvocidib Phase II NCT02520011 
PI3K inhibitor Rigosertib Phase I/II NCT01167166 
PIM kinase inhibitor LGH447 Phase I NCT02078609 
Nuclear export 
inhibitor 
   
XPO1 (CRM1 
inhibitor) 
selinexor Phase II NCT03071276 
Cytotoxic agents Vosaroxin  Phase III NCT01191801 
Nucleoside analogs Sapacitabine Phase III NCT01303796 
 Clofarabine Phase III  NCT00703820 
 Cladribine Phase III NCT03384212 
Abbreviations: IDH1/2: isocitrate dehydrogenase; DOT1L: DOT1-like histone 
H3K79 methyltransferase; LSD1: Lysine-specifi histone demethylase 1A; FLT3: 
FMS-like tyrosine kinase 3; MDM2: Mouse double minute 2 homolog; PLK: 
polo-like kinase; CDK: cycline-dependent kinase; PI3K: phosphoinositide 
3-kinase inhibitor; PIM: proto-oncogene serine/threonine-protein kinase; XPO1: 
exportin 1, also known as chromosomal maintenance 1 (CRM1). 
 
1.3. Castration-resistant prostate cancer (CRPC) 
SEER cancer statistics review 1975-201467 and cancer statistic in 201768,49 
reported that prostate cancer was the common type of cancer in men in the US, 
accounting for about 20-30% of all new cases of cancer. The mortality was 4.4%, 
and 26,730 people was projected to die from PCa in the US in 2017. Risk factors 
for prostate carcinogenesis included age, dietary habit (e.g., smoking), family 
history, and inherited genetic conditions (e.g., Lynch syndrome, BRCA1 and 
BRCA2 mutations). PCa was primarily localized in prostate (79%), partially spread 
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(12%), or metastasized (5%). For metastatic PCa, the 5-year survival rate was 
only 29.8%67. During cancer progression, symptoms include decreased urinary 
stream, frequent urination at night, pain, blood or burning with urination, nocturia 
or incomplete bladder emptying. In advanced or metastatic PCa, pain in spine, 
hips or bone may also be presented. Current treatments for PCa rely on surgery, 
hormonal therapy, radiation therapy or chemotherapy. Hormonal therapy may be 
used with surgery and radiation therapy is used for patients with more advanced 
PCa. Chemotherapy becomes a main option when hormone treatments or 
surgery are not effective. The standard treatment contains docetaxel/cabazitaxel 
along with steroid drug prednisone or androgen-deprivation therapy (ADT)69. 
Huggins and Hodges70 for the first time identified and demonstrated 
reliance of prostate cancer on androgen. Since then, ADT has become the 
standard of care for patients, aiming to achieve disease stabilization by lowering 
the source of androgen. ADT can be achieved through surgical and medical 
castration. Surgical castration excises both testes and reduces major circulating 
androgen testosterone by 90%71. Medical castration pharmacologically reduces 
androgen production. For example, LHRH (luteinizing hormone-releasing 
hormone) agonists and antagonists are used to decrease luteinizing hormone, 
thus preventing testicular testosterone production. Despite the initial benefit, 
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patients who receive ADT frequently progress to castration-resistant prostate 
cancer (CRPC) within 2-3 years72. This progression is driven by several 
mechanisms including altered steroidogenesis, aberrant signaling activation, AR 
or AR co-regulators mutations, the presence of truncated AR, etc73. In CRPC, AR 
signaling continues to play the key role in PCa maintenance and progression74. 
Current treatments either approved by FDA or in clinical trials are mainly targeting 
AR, mutant AR, and androgen synthesis. 
1.3.1. Epidemiology 
According to latest cancer statistics in 2017 in USA68, prostate cancer (PCa) 
was the third-leading cause of men deaths in 2017 with an estimated 26,730 
cases in the USA. Nearly 161,360 men would be diagnosed with prostate cancer 
during 2017. 1 in 8 of men would be possibly diagnosed with PCa in their whole 
life in the US68. Prostate cancer was affecting around 1.1 million in the world and 
causing 0.3 million deaths in 2012, with the second highest incidence rate and 
fifth highest mortality in all cases of cancers in men75. In race and ethnicity, PCa 
was much more common in blacks (42.8%) than whites, with around twice higher 
risk rate than non-hispanic whites (18.7%), five-fold higher risk rate than 
Asian/Pacific islander (8.8%)68. Based on age-adjusted data from 2010-201467, 
people were usually diagnosed with PCa within an age range 65-74, with a 
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median age of 66 at diagnosis. The percent of patients who die from PCa was the 
highest within an age range 75-84, with a median age of 80 at death. 
1.3.2. Pathogenesis 
The specific pathogenesis of PCa is not fully understood, but several 
approaches (e.g., cellular signaling regulation mapping, genome-wide analysis, 
microRNAs profiling, etc.) have performed and identified potential causes for 
onset and advanced PCa. Many factors, including gene abnormalities and 
non-gene aberrations, contribute to the development of PCa. 
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Figure 6. Structure of wild type AR protein, AR gene, AR RNA transcript, and 
common gain-of-function AR-Vs in CRPC. AR-V1, AR-V3, AR-V7, and AR-V12 
are abundant and associated with resistance to hormonal therapy76. AR-V7 and 
AR-V3 may be the major androgen-independent drivers of AR-regulated gene 
expression in CRPC77,78. The picture was modified based on Brinkmann 198979 
and Lallous 201380. NTD= N-terminal domain; DBD= DNA-binding domain; LBD= 
ligand-binding domain; AR-Vs= AR splice variants; U= unique nucleic acid 
sequences not found in wild type AR; Zn= zinc finger; AF1/5= activation function 
1/5. 
 
AR signaling abnormalities are emphasized in the development and 
maintenance of androgen-dependent or independent PCa. As the initial mediator 
of AR signaling, approximately 33% of recurrent PCa and up to 80% CRPC show 
enhanced AR activity as a result of AR gene amplification, AR mRNA 
overexpression, and AR protein upregulation81,82. In androgen-dependent PCa, 
overexpressed AR renders PCa cells high sensitivity to sense and uptake 
androgen despite castration83. In androgen-independent PCa, AR activation is 
persistent, and driven by androgen-independent mechanisms such as MAP 
kinase84 or HER family kinase85. Interestingly, AR protein itself is a transcriptional 
factor regulating expression of several miRNAs such as miR-19a86, miR-27a86, 
miR-133b86, miR-14887, miR-125b88, etc. miR-125b is overexpressed either in 
PCa cell lines or PCa patient samples, and can induce androgen-independent 
PCa proliferation by downregulating Bak188, suggesting the oncogenic role of 
miR-125b. In CRPC, assessments of clinical patients with CRPC revealed that 
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androgen levels are not remarkably reduced when compared to control tissues89, 
suggesting the intratumoral enhancement in androgen synthesis or 
maintenance90. In parallel with androgen level results, subsequent gene 
expression studies revealed the increased expression of androgen-synthesizing 
enzymes such as CYP17A1 and SRD5A191,92. Currently, CRPC has been 
considered as "androgen-independent" or " hormone-refractory", and AR 
signaling axis still plays the central role in maintenance and progression of CRPC. 
In this context, two FDA-approved agents, abiraterone93 (a CYP17A1 inhibitor) 
and enzalutamide94 (an anti-androgen) are approved for the treatment of CRPC. 
Despite these current therapies, the treatment for CRPC is still challenging due to 
observed drug resistance95. Abiraterone or orteronel targeting androgen synthetic 
enzyme CYP17A1 with high affinity can reduce the circulating level of androgen, 
but the resistance has emerged in patients receiving these agents and is 
associated with the upregulation of CYP17A1, constitutively active full-length AR 
or the presence of AR splice variants (AR-Vs)96 (Figure 6). Therefore, these 
resistances to CYP17A1 inhibitors observed in clinical samples limit their 
applications in patients with CRPC and encourage researchers to explore other 
targets. Targeting AR ligand binding domain (LBD) has become appealing. Given 
that AR signaling initiates by binding to dihydrotesterone (DHT), anti-androgens 
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are developed to compete with DHT with higher affinity, thus antagonizing AR 
signaling. However, compelling evidence has also shown resistant mechanisms 
to AR LBD agents such as bicalutamide and enzalutamide. The bicalutamide 
competes with AR substrate (DHT) and weakens AR binding to chromatin or 
coactivator proteins, but it fails to inhibit AR translocation into the nucleus; thereby, 
AR can still proceed transcription stimulation97,98. Furthermore, a mutation in 
codon 741 or AR overexpression confers bicalutamide agonistic activity instead of 
presumable antagonistic activity99,100. The other enzalutamide binds AR with high 
affinity and further blocks AR translocation into the nucleus, but it has no 
considerable efficacy in CRPC mouse model where increased AR-Vs are 
present77. Overall, multiple factors including promoted androgen biosynthesis, AR 
mutation, decreased recruitment of AR coactivators or corepressors, and 
increased AR-Vs level are implicated in resistance to current AR LBD-targeting 
agents. It is noted that these resistant mechanisms are closely related to CRPC's 
characteristics distinct from PCa cells. In CRPC cells, AR-Vs lacking C-terminal 
ligand-binding domain (LBD) are constitutively active and primarily present in the 
nucleus with AR transcriptional activities101. AR-V7 and ARv567es were 
commonly observed and linked to CRPC progression and metastasis95. Clinically, 
AR-Vs are implicated in 40%-50% CRPC patients102. Structurally, although AR-Vs 
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lack intact LBD and some even have incomplete DNA-binding domains 
(DBD)78,77,103, AR and most AR-Vs share intact N-terminal domain (NTD) where 
activation function-1 region interacts with many partner proteins such as CBP104 
and RAP74105 (Figure 6). It is AR NTD that is responsible for the formation of 
transcriptional complex, thus maintaining transcriptional activities of AR/AR-Vs 
regardless of LBD. Therefore, the regimen targeting both AR and AR-Vs is 
considered to be most effective in anti-CRPC therapy (Figure 7). 
 
Figure 7. Summary of AR-dependent mechanisms of castration resistance. This 
picture was modified base on Tilki 201680. Abbreviations: AR: androgen receptor; 
LBD: AR ligand-binding domain; ADT: androgen-deprivation therapy; MAPK: 
mitogen-activated protein kinase; HER family: epidermal growth factor receptor 
family. 
 
Family inheritance and lifestyle difference have been recognized as 
important risk factors leading PCa, as indicated by world-wide epidemiological 
23 
 
studies106,107. PCa often occurs in familial aggregation, and 5%-10% of prostate 
cancer cases and up to 40% of early onset diseases are estimated to stem from 
inherited gene susceptibility108. Besides, the risk of developing PCa is 2-3 fold 
higher in men with family history than men without the family history109. Recent 
studies have further revealed that hereditary factor is the determinant of PCa 
instead of the lifestyle110. Approximately 42% risk leading to PCa could be 
explained by inherited genetic factors110. Therefore, much effort has been made to 
identify high-risk gene loci which are relevant to link PCa pathogenesis. Early PCa 
genetic linkage analysis identified HPC1, HPCX, ELAC2, PCAP, HPC20, etc111 
gene loci to be associated with familial PCa. Some studies have suggested their 
linkage with PCa predisposition, for example, HPC1 is shown to be related to the 
advanced PCa within families112, but clinic relevance between identified 
chromosome loci and PCa occurrence still needs to be established. Although the 
linkage analysis appeared to be a useful tool, it shows inconsistent results113 and 
cannot recognize the low-moderate risk of developing PCa. Therefore, a new 
genome-wide association study (GWAS) is conducted and found 76 susceptibility 
loci with low penetrance, accounting for 30% familial risks of PCa114. Among 76 
GWAS-selected loci, 8q24 is the firstly identified region and shown to harbor six 
(the largest number of) single nucleotide polymorphisms (SNPs)115,116,117. The 
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region where 8q24 locus is located is nearby MYC gene area known to be an 
oncogene which is associated with many types of cancers including the prostate 
cancer. Also, 8q24 was found to affect the MYC gene expression118. In addition to 
MYC gene, multiple genes including MSMB119, KLK3120, AR121, etc., are also 
involved in pathogenesis of PCa. With advent of advanced genome-wide studies 
(e.g., GWAS), further validation at public health and personalized level is 
ongoing114.  
Additionally, PCa pathogenesis could be attributed to genome changes and 
lesions as a result of oxidative damage. Oxidative stress has been well studied as 
a connector linking exo/endogenous factors with carcinogenesis122. During 
chronic oxidative stress, many DNA changes may occur in cellular genome, 
including DNA base oxidation/mutation, DNA strands breaking, DNA-protein 
crosslink123. As a result of genetic aberrations, normal cells may start the 
transformation to neoplastic cells which subsequently progress to malignant cells. 
Since oxidative stress initiated by electrophiles or oxidants are detoxified or 
antagonized by antioxidant defense such as glutathione-S-transferase (GST)124, 
these genes encoding antioxidant systems are highly susceptible to 
dysregulation125 during carcinogenesis. Over recent years, π-class 
glutathione-S-transferase P1 (GSTP1) gene promotor methylation has been 
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recognized as a marker of the transformation of normal cells to prostatic 
intraepithelial neoplasia (PIN) and small PCa lesions126,127. GSTP1 methylation 
leads to the declined expression of GSTP1128 and is detected in 6% prostatic 
intraepithelial atrophy129, 69% of PIN DNA specimens and 90% of PCa DNA 
specimens127. Besides, GSTP1 repression occurs at the earliest stage of prostatic 
carcinogenesis and further correlates with the occurrence of prostate cancer127. 
Somatic genome damage resulting from GSTP1 defects induces neoplastic 
transformation, and PCa carcinoma cells possessing loss of GSTP1 function are 
subject to genome damage which leads to malignant progression127,130. Clinically, 
more than 40% of patients with the high-grade PIN will progress to PCa within 
three years131. These pre-cancerous events (GSTP1 methylation, PIN, and PCa 
lesions) may provide the compelling evidence for elucidation of PCa pathogenesis 
and novel targets for PCa prevention or treatment. Interestingly, although GSTP1 
is downregulated in most of PCa cells (e.g., LNCaP, DU145)132, it is 
overexpressed in androgen-independent CRPC PC-3 cells132 and associated with 
chemoresistance in PCa133. Besides PCa, GSTP1 protein overexpression is 
associated with multiple drug resistance and tumor progression134 in other types 
of cancer. Therefore, GSTP1 is a valuable target for the treatment of PCa, 
especially for androgen-independent PCa. 
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Figure 8. Gene abnormalities and non-genetic aberrations cause the 
pathogenesis of PCa. 
 
Recent advances in explanation of PCa pathogenesis, including genome 
instability, damage, oxidative stress accumulation and AR signaling aberration, 
significantly contribute to the comprehensive molecular biological networking that 
modulates PCa initiation and progression (Figure 8). However, there is no clear 
answer fully unrolling this puzzle to date. Therefore, much clinical efforts and 
further functional clarification are being undertaken for connecting molecular 
characterization with PCa tumorigenesis. 
1.3.3. Potential therapeutic targets and treatments 
Treatment options of PCa depend on multiple factors such as diagnosis, 
stages of PCa development, age, overall health, life expectancy, quality, etc. They 
contain active monitoring, surgery, radiation, cryotherapy, hormone therapy, 
chemotherapy, vaccine treatment, bone-directed treatment135. In general, one 
treatment option will be used for one patient case, but sometimes they may be 
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combined. For example, surgery is the common treatment for patients with 
localized PCa, radiation and hormone therapy are usually combined for the 
treatment of metastatic PCa. Chemotherapy is applied when hormone therapy no 
longer works. Docetaxel alone or combination with prednisone is the first-line 
option. Recent advances in cancer biology of PCa revealed the essential role of 
AR signaling axis in progression and maintenance of CRPC136 (Figure 7), so 
plenty of novel "AR signaling-targeting drugs" have been approved (e.g., 
enzalutamide and abiraterone) or under clinical investigation (e.g., EPI-506)137. 
Herein, we mainly focus on the chemotherapeutic drugs for the treatment of 
advanced PCa, especially CRPC, and summarized their targets and clinical status, 
as shown in the following table. 
Table 2 Drugs targets and therapeutic agents for the treatment of PCa/CRPC. 
This table was adapted from Yoo 2016137. 
Potential 
Targets/Action 
Mechanism 
Agents Clinical Status Clinical Trials 
Cytotoxic 
chemotherapy 
   
 Carboplatin Phase II NCT02311764 
 Docetaxel 
Approved in 
2004 
 
 Cabazitaxel 
Approved in 
2010 
 
Radiation therapy Radium-223 
Approved in 
2013 
 
AR targeting    
 Bicalutamide Approved in  
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1995 
 Nilutamide 
Approved in 
1996 
 
 Flutamide 
Approved in 
1989 
 
 
Galeterone 
(AR&CYP17A1) 
Phase II NCT01709734 
 Enzalutamide 
Approved in 
2012 
 
 ARN-509 Phase III NCT01946204 
 AZD-3514 Phase I NCT01162395 
 ODM-201 Phase III NCT02200614 
 SHR3680 Phase I/II NCT02691975 
 EPI-506 Phase I/II NCT02606123 
Androgen 
synthesis 
(CYP17A1) 
   
 Abiraterone 
Approved in 
2011 
 
 TAK-700 Phase III NCT01707966 
 TOK-001 Phase II NCT01709734 
 VT-464 Phase II NCT02012920 
 
ODM-204 (dual 
inhibitor 
CYP17A1/AR) 
Phase I/II NCT02344017 
Kinase inhibitors    
AKT inhibitor AZD5363 Phase I/II NCT02121639 
PI3K inhibitor 
LY3023414 
(PI3K&mTOR) 
Phase II NCT02407054 
 
BKM120 
(Buparlisib) 
Phase I NCT01634061 
Aurora A kinase 
inhibitor 
MLN8237 
(Alisertib) 
Phase I/II NCT01848067 
mTOR inhibitor MLN0128 Phase II NCT02091531 
 
Everolimus 
(RAD001) 
Phase II NCT00629525 
CDK inhibitor LEE011 (ribociclib) Phase I/II NCT02494921 
Tyrosine kinase TK1258 (Dovitinib) Phase II NCT01741116 
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inhibitors (FGFR) 
PARP inhibitor Olaparib Phase III NCT02987543 
Proteasome 
inhibitor 
Carfilzomib Phase II NCT02047253 
TGF-β inhibitor Galunisertib Phase II NCT02452008 
XPO-1 KPT-330 Phase II NCT02215161 
Immunotherapy    
Antibody Ipilimumab Phase III NCT01057810 
Antibody 177lu-J591 Phase III NCT00916123 
Vaccine DCVAC Phase III NCT02111577 
Vaccine GX301 Phase II NCT02293707 
Abbreviations: AR: androgen receptor; CYP17A1: cytochrome P450 17A1; AKT: 
protein kinase B; PI3K: phosphoinositide 3-kinase; mTOR: mammalian target of 
rapamycin; CDK: cyclin-dependent kinase; FGFR: fibroblast growth factor 
receptor; PARP: poly (ADP-ribose) polymerase; TGF-β: transforming growth 
factor beta; XPO-1: exportin-1. 
 
1.4. Overview of projects 
Over the last few decades, the relationship between oxidative stress and 
electrophiles has been gradually unveiled. In addition to covalent modification of 
oncogenic effectors, electrophiles also exhibit multiple anti-cancer activities 
through elevating ROS. ROS such as hydroxyl radicals, superoxide anion, and 
hydrogen peroxide is found to be the direct mediator to regulate oxidative stress in 
cells138. ROS are generated in many organelles, including major mitochondria and 
endoplasmic reticulum139. The role of ROS is identified as "Good and Evil"140. The 
"Good" stems from its involvement in the regulation of many biological functions 
such as cell proliferation, apoptosis, and senescence. ROS overproduction, the 
"Evil", is linked to cytotoxicity through harmful effects on cellular DNA, lipids, and 
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proteins. These side effects of ROS are not only nontoxic but also fully exploited 
by cancer cells for cell proliferation, differentiation, and chemotherapeutic 
resistance141. Molecular mechanism studies reveal that increased activity or 
expression of oxidants and downregulation of antioxidant system contribute to 
ROS overproduction, while upregulation of some antioxidants is found to balance 
it65. Therefore, a dynamic redox homeostasis between oxidative stress and 
anti-oxidative defense is vital to maintaining phenotype of cancer cells. Given the 
aberrant redox status (e.g., vulnerability to higher ROS and dysregulation of 
antioxidant systems) in cancer cells, small molecular chemicals aimed to increase 
intracellular ROS levels have been explored in cancer therapy, which is referred to 
as electrophilicity-based anti-cancer prooxidant strategy25. ROS-inducing triggers 
include electrophiles (e.g., PL, β-phenylethyl isothiocyanate), acids (e.g., lactic 
acids), oxidants (e.g., hydrogen peroxide), enzyme inhibitors, (e.g., Buthionine 
sulfoximine) and GSH-depleting agents (e.g., diethylmaleate and DEM), etc. 
Among them, the class of electrophiles is the most attractive due to their high 
potency and great selectivity over cancer cells142. PL is a representative of 
electrophiles (Figure 2) and acts via covalent protein modification and ROS 
elevation, so we focus on exploitation of PL and PL chemical scaffolds to discover 
and develop novel drugs for the treatment of AML and PCa. 
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Chapter 2 focuses on PL combination with SAHA and following PL-HDACi 
hybrids for the treatment of AML. Chapter 3 focuses on the design, synthesis, and 
characterization of ROS/RNS-sensitive SAHA prodrugs, which in turn serves to 
increase the selectivity of PL-HDACi hybrids over cancer cells. Chapter 4 focuses 
on the structural modification of PL for enhancing the potency of PL and 
PL-HDACi hybrids against prostate cancer cells. 
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CHAPTER 2 DESIGN, SYNTHESIS, AND BIOLOGICAL CHARACTERIZATION 
OF PL-HDACi HYBRIDS AS ANTI-AML AGENTS 
In this chapter, some of text were reprinted or modified from: Liao Y, Niu X, Chen 
B, et al. Synthesis and Antileukemic Activities of Piperlongumine and HDAC 
Inhibitor Hybrids against Acute Myeloid Leukemia Cells. Journal of Medicinal 
Chemistry, 2016, 59 (17): 7974-7990. 
2.1. Rationale for the hybridization of PL and HDACi 
The current treatment for almost all subtypes of AML (except acute 
promyelocytic leukemia) is to use a combination of cytosine arabinoside (Ara-C or 
cytarabine) and daunorubicin, which has not been changed for more than three 
decades. Treatment failure is mainly due to resistance to chemotherapy and 
disease relapse arising from leukemia stem cells (LSCs)143. The discovery of 
innovative therapeutic agents for AML treatment represents an urgent and 
essential medical need.  
HDACs are implicated in tumorigenesis of acute leukemia and have been 
studied as therapeutic targets. HDAC inhibitors display attractive anti-cancer 
mechanisms of action, including transcriptional activation of p53144, inactivation of 
NF-κB145, upregulation of CDKN1A146, downregulation of pro-angiogenic factors 
such as VEGF (Vascular endothelial growth factor)147, and induction of caspase-3 
protease activity148. A HDACs inhibitor (HDACi), suberoylanilide hydroxamic acid 
(Vorinostat, SAHA), was approved by FDA to treat cutaneous T-cell lymphoma 
(CTCL), and has been demonstrated anti-tumor activities as a single dose or in 
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combination with other agents in solid and hematological tumors at doses 
tolerated by normal cells149. HDACis not only induce leukemia cell death by DNA 
damage, ROS elevation, downregulation of DNA repair system (e.g., RAD51, 
CHK1, BRCA1 etc.)150,151,152, and disruption of pro-/anti-apoptotic balance153, but 
also reduce the population of LSCs linking to cancer relapse154,155. However, the 
clinical efficacy of SAHA as single agent drug in AML patients is poor, the reason 
might be associated with upregulation of antioxidant defense pathways in AML 
cells156. To overcome potential resistance and/or enhance efficacy, SAHA was 
combined with other potent anti-cancer agents. For example, SAHA was reported 
to synergistically interact with AZD1775 against null-p53 and wt p53 AML cells via 
inactivation of cell cycle regulator CHK1, upregulation of γH2A, and cell arrest at 
early S phase157. Besides, SAHA was paired with MK8776 (a CHK1 inhibitor), and 
this combination displayed synergistically inhibitory effects on multiple p53-wt or 
-deficient leukemia cell lines by impacting cell cycle checkpoints, downregulating 
expression of DNA replication (e.g., Cdt1) or repair-related proteins (e.g., CtIP and 
BRCA1)158. Taken together, HDACs could be rationally targeted for cancer 
treatment, and HDACi could be further exploited and combined with other 
DNA-damaging agents for the treatment of leukemia.  
Piperlongumine (PL) extracted from long pepper was reported to 
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selectively kill cancer cells in low micromolar concentration and to inhibit tumor 
growth in vivo3,21. Because of electrophilicity, PL shows diverse mechanisms of 
actions against various cancers. PL-induced redox imbalance, such as ROS 
elevation and GSH depletion3, plays a key role in its anti-cancer activities. For 
example, PL could kill primary myeloid leukemia31 and CD34+ AML cells from 
patient samples12 via increased oxidative stress. Besides, PL killed LSCs with an 
EC50 of 380 nM
159 by increasing ROS level, inducing various DNA lesions (mainly 
double-strand breaks), and inhibiting homologous recombination (HR) by using 
DNA repair-deficient DT40 cell lines160. PL could also reduce pancreatic tumor 
burden through ROS-mediated DNA damage, as suggested by increased level of 
8-hydroxy-2`-deoxyguanosine (8-OHdG) in pancreatic tumor cells161. In 
triple-negative breast cancer cells, PL induced DNA fragmentation and p21 mRNA 
expression162. 
Consequently, HDACi SAHA-induced anti-AML activities, such as DNA damage, 
downregulation of DNA-related enzymes, and elevation of oxidative stress, 
overlap with the major properties of PL. Based on the understanding of the 
anti-cancer mechanisms of SAHA and PL, we hypothesized that SAHA and PL 
may synergistically increase ROS levels and enhance DNA damage in AML cells, 
and the SAHA resistance associated with antioxidant upregulation could be 
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potentially overcome by the electrophilic PL, which is known to decrease 
antioxidant defense3. The cooperative and complementary anti-AML properties of 
SAHA and PL form a scientific rationale to design new hybrid drugs against AML. 
Different from co-treatment of SAHA and PL, we performed a 
"hybridization" strategy with HDACi and PL pharmacophores, affording single 
molecular entity (1-58) harboring both SAHA and PL activities. Compared to the 
simple combination of two drugs, this approach more efficiently co-localizes 
synergistic pharmacophores and greatly simplifies optimization of drug-like 
properties, PK and dose-toxicity profiles at advanced drug discovery/development 
stages163. We hypothesized that synergistic/additive anti-AML effects of SAHA 
and PL can be realized by PL-HDACi hybrid drugs through cooperatively 
enhanced DNA damage, upregulation of apoptotic, and downregulation of 
anti-apoptotic pathways. 
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2.2. Design and synthesis of PL-HDACi hybrid drugs 
 
Scheme 1. Synthetic route of PL-HDACi hybrids. Reagents and conditions: (a) 
(BOC)2O, DMAP, t-BuOH, THF; (b) concentrated sulfuric acid, MeOH, reflux; (c) 
K2CO3, DMF, 70 °C; (d) LiOH, THF, H2O; (e) (1) pivaloyl chloride, TEA, THF, 
−20 °C; (2) lactam, n-BuLi, THF, −78 °C; (f) (1) oxalyl chloride, THF, −20 °C; (2) 
lactam, nBuLi, THF, −78 °C (g) 20% TFA, DCM; (h) diazomethane, DCM; (i) 
HBTU, NH2OTHP, DIPEA, DMF; (j)10% TFA, MeOH. 
 
In order to incorporate both PL and HDACi activities into a single chemical 
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entity, the prototype chimeric molecule 1-58 was designed by introducing a 
seven-carbon linker at the 4’ position of PL. The linker was further connected to 
the hydroxamic acid moiety, a zinc binding group (ZBG), to mimic the partial 
structure of SAHA (Scheme 1). The modified PL structure served as a “cap” that 
could bind at the surface of HDAC enzymes. Published PL structure-activity 
relationship (SAR) studies suggested that the C2-C3 olefin was responsible for 
GSH conjugation via Michael addition and was vital for ROS induction. The C2 
substituent could potentially affect the chemical reactivity of C2-C3 olefin and 
impact anticancer potency of PL. For instance, electron-withdrawing C2-chloride 
increases, while C2-methyl group decreases cytotoxicity of PL to cancer cells21, 164. 
After conjugation with cellular GSH, close interactions of PL-GSH conjugate with 
GSH-binding proteins could increase the availability of electrophilic C7-C8 olefin 
to protein thiol groups and therefore promote covalent protein modification. 
Elimination of the C7-C8 double bond has been shown to reduce cytotoxicity,21 
which might be a consequence of decreased PL covalent protein binding. To 
investigate how the C2 substituent and the C7-C8 olefin affect the overall 
anti-AML properties of 1-58. Compound 3-35 with a C2-Cl substituent and 
3-31/3-98 (Scheme 1) without the internal C7-C8 double bond were also 
synthesized and tested in cell culture models. Compared to parental drug, either 
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SAHA or PL, we expected that the C2-C3 olefin of 3-31 or 3-98 could partially 
retain anti-cancer properties of PL and still work cooperatively with the HDACi 
functional group to achieve improved anti-AML activities. Instead of having both 
HDACi and PL pharmacophores, compounds 27, 28, 35 and 36 are close 
structural analogues of 1-58 or 3-35 with just one active pharmacophore (Scheme 
1), e.g., ZBG of 1-58 or 3-35 was replaced by a methyl ester in 27 and 28 
respectively, and the electrophilic C2-C3 olefin of 1-58 was blocked by either a 
C3-methyl substituent (compound 39) or hydrogen saturation (compound 40).  
These compounds were used to make comparisons with 1-58 and 3-35 to 
demonstrate both PL and HDACi pharmacophores are required and contribute to 
the observed superior anti-AML properties. 
The synthesis of 1-58/3-35 and 3-31/3-98 scaffold was accomplished from 
commercially available sinapinic acid 3 and syringic acid 5, respectively (Scheme 
1). Carboxylic acids 3 and 5 were first converted to corresponding methyl esters 4 
and 6 followed by the alkylation of phenol hydroxyl groups with compound 2, a 
t-butyl ester of 7-bromoheptanoic acid to afford 7 and 8 respectively. Free 
carboxylic acids 9 and 10 were obtained via basic hydrolysis of methyl esters 7 
and 8, while the t-butyl esters of these molecules were intact. In order to conduct 
SAR studies of PL-like pharmacophores, α,β-unsaturated lactam 11165, its 
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analogues 12164 which has a C2-Cl substituent, and 13166 with a C3-methyl group 
were synthesized according to published procedure with slight modifications and 
compound 14, δ-valerolactam, was purchased. Different lactams 11-14 were 
de-protonated by n-BuLi and then coupled with pivaloyl chloride-activated 9 and 
10 respectively, to afford 15-20. In following steps, t-butyl esters were cleaved 
using TFA and the obtained acids 21-26 were coupled to THP-protected hydroxyl 
amine. Final acidic de-protection using 10% TFA in MeOH gave hydroxamic 
acid-containing 1-58, 3-35, 3-31, 3-98, 39, and 40. Methyl esters 27 and 28 were 
prepared from 21 and 22 by using diazomethane as esterification reagent 
respectively. Synthetic intermediates and final products were characterized using 
1H, 13C NMR and mass spectrometry; for the biological studies, purity of the 
compounds was further confirmed using HPLC analysis. 
2.3. Chemistry 
Tert-butyl 7-bromoheptanoate (2) 
7-Bromoheptanoic acid (1.11 g, 5.3 mmol, 1.0 eq) and Boc anhydride (1.38 
g, 6.3 mmol, 1.2 eq) were mixed in tert-butyl alcohol (5 mL). After the mixture was 
stirred at room temperature for 10 min, DMAP (195 mg, 1.6 mmol, 0.3 eq) was 
added and the reaction mixture was stirred for another 2 h. Upon completion, the 
solvent was removed under reduced pressure and the residue was re-dissolved in 
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ethyl acetate and was washed with water and brine, dried over anhydrous Na2SO4. 
Purification by flash chromatography (Hex/EA, 20/1) afforded product (colorless 
oil, 570 mg, 40%). 1H NMR (600 MHz, CDCl3): δ (ppm) 3.38 (t, J=6.6Hz, 2H), 2.19 
(t, J=7.2Hz, 2H), 1.82-1.86 (m, 2H), 1.55-1.60 (m, 2H), 1.40-1.45 (m, 2H), 1.42 (s, 
9H), 1.29-1.34 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.06, 80.01, 35.39, 
33.81, 32.55, 28.16, 28.09, 27.81, 24.83. 
(E)-Methyl 3-(4-hydroxy-3,5-dimethoxyphenyl)acrylate (4) 
Sinapinic acid (1.03 g, 4.6 mmol, 1.0 eq) was dissolved in methanol (20 mL) 
followed by addition of several drops of conc. H2SO4. The reaction mixture was 
refluxed for 6 h. Upon completion, the reaction mixture was cooled to ambient 
temperature and solvent was removed under vacuum. The resulting residue was 
diluted with ethyl acetate and washed using sat. aq. NaHCO3, water and brine, 
and dried over anhydrous Na2SO4. Purification by flash chromatography (Hex/EA, 
2:1) afforded product (yellow oil, 1.1 g, 99%). 1H NMR (600 MHz, CDCl3): δ (ppm) 
7.55 (d, J=15.6Hz, 1H), 6.72 (s, 2H), 6.26 (d, J=15.6Hz, 1H), 5.79 (s, 1H), 3.89 (s, 
6H), 3.76(s, 3H). 13C NMR (125 MHz, CDCl3): δ (ppm) 167.61, 147.18, 145.15, 
137.13, 125.77, 115.41, 105.00, 56.27, 51.62. 
Methyl 3,5-dimethoxy-4-hydroxybenzoate (6) 
1H NMR (600 MHz, CDCl3): δ (ppm) 7.32 (s, 2H), 6.04 (s, 1H), 3.93 (s, 6H), 
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3.90 (s, 3H). 13C NMR (125 MHz, CDCl3): δ (ppm) 166.85, 146.59, 139.16, 120.98, 
106.57, 56.36, 52.07. 
(E)-tert-butyl 7- (2,6-dimethoxy-4- (3-methoxy-3-oxoprop-1-enyl) phenoxy ) 
heptanoate (7) 
Compound 2 (570 mg, 2.1 mmol, 1.1 eq), compound 4 (476 mg, 2.0 mmol, 
1.0 eq) and K2CO3 (838 mg, 6.0 mmol, 3.0 eq) were mixed in DMF (4 mL). The 
reaction mixture was stirred at 60oC overnight. The reaction mixture was cooled to 
room temperature and diluted with water. After extraction using ethyl acetate three 
times, the combined organic phase was washed with water and brine, and dried 
over anhydrous Na2SO4. Purification by flash chromatography (Hex/EA, 6:1) 
afforded product compound 7 (colorless oil, 630 mg, 75%). 1H NMR (600 MHz, 
CDCl3): δ (ppm) 7.55 (d, J=15.6Hz, 1H), 6.69 (s, 2H), 6.28 (d, J=15.6Hz, 1H), 3.94 
(t, J=6.6Hz, 2H), 3.81(s, 6H), 3.75 (s, 3H), 2.16 (t, J=7.2Hz, 2H), 1.67-1.72 (m, 
2H), 1.53-1.68(m, 2H), 1.41-1.46(m, 2H), 1.38 (s, 9H), 1.28-1.33(m, 2H). 13C NMR 
(125 MHz, CDCl3): δ (ppm) 173.16, 167.36, 153.60, 144.89, 139.40, 129.57, 
116.76, 105.23, 79.84, 73.41, 56.07, 51.61, 35.49, 29.86, 28.80, 28.04, 25.47, 
25.01. HRMS (ESI): calcd for [C23H35O7+H]
+, 423.2383; found, 423.2404. 
Methyl 4-(7-tert-butoxy-7-oxoheptyloxy)-3,5-dimethoxybenzoate (8). 
The flash was charged with compound 6 (1.8 g, 8.2 mmol) and compound 
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2 (2.4 g, 9.1 mmol). DMF (10 mL) and potassium carbonate (3.4 g, 24.7 mmol) 
were added at room temperature. The reaction was allowed to undergo at 80 oC 
overnight. Once completed, the resulting mixture was washed with water and 
extracted with DCM three times, and then the organic phase was dried over 
Na2SO4 for 30 min. Purification done by flash chromatography (Hex/EA, 8:1) 
produces compound 8 (colorless oil, 3.7 g, 94%). 1H NMR (600 MHz, CDCl3): δ 
(ppm) 7.26 (s, 2H), 3.99 (t, J=7.2Hz, 2H), 3.87 (s, 3H), 3.86 (s, 6H), 2.18 (t, 
J=7.2Hz, 2H), 1.70-1.75 (m, 2H), 1.55-1.60 (m, 2H), 1.42-1.47 (m, 2H), 1.41 (s, 
9H), 1.31-1.36 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.20, 166.75, 
153.12, 141.43, 124.88, 106.74, 79.88, 73.37, 56.16, 52.16, 35.52, 29.89, 28.82, 
28.08, 25.48, 25.03. HRMS (ESI): calcd. for [C21H32O7∙Na
+], 419.2046; found, 
419.2046. 
(E)-3-(4-(7-tert-butoxy-7-oxoheptyloxy)-3,5-dimethoxyphenyl)acrylic acid (9). 
Compound 7 (588 mg, 1.4 mmol, 1.0 eq) was dissolved in THF/H2O (5 
mL/5 mL) to which LiOH (40 mg, 1.7 mmol, 1.2 eq) was added. The reaction 
mixture was stirred at room temperature for overnight. Upon completion, 2N HCl 
was added to acidify the reaction and the solution was extracted with ethyl acetate 
three times. The collected organic phase was washed with water and brine, dried 
over anhydrous Na2SO4. Evaporation of solvent afforded product compound 9 
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(yellow oil, 600 mg, 100%) which was used in the next step without further 
purification. 1H NMR (600 MHz, CDCl3): δ (ppm) 7.68 (d, J=15.6Hz, 1H), 6.75 (s, 
2H), 6.33 (d, J=15.6Hz, 1H), 3.98 (t, J=6.6Hz, 2H), 3.85 (s, 6H), 2.19 (t, J=7.2Hz, 
2H), 1.71-1.75 (m, 2H), 1.56-1.61 (m, 2H), 1.43-1.48 (m, 2H), 1.42 (s, 9H), 
1.33-1.37 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.31, 172.21, 153.66, 
147.04, 139.82, 129.26, 116.31, 105.57, 79.97, 73.50, 56.13, 35.54, 29.89, 28.83, 
28.09, 25.49, 25.04. 
4-(7-tert-butoxy-7-oxoheptyloxy)-3,5-dimethoxybenzoic acid (10) 
Compound 10 was made from 8 (3.7 g, 7.7 mmol) as described for 
compound 9. Product was obtained as yellow oil (1.7 g, 47%). 1H NMR (600 MHz, 
CDCl3): δ (ppm) 7.37 (s, 2H), 4.05 (t, J=7.2Hz, 2H), 3.90 (s, 6H), 2.23 (t, J=7.8Hz, 
2H), 1.74-1.79(m, 2H), 1.59-1.64 (m, 2H), 1.46-1.51(m, 2H), 1.44 (s, 9H), 
1.35-1.39 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.33, 171.37, 153.17, 
142.18, 124.04, 107.34, 79.99, 73.44, 56.18, 35.53, 29.90, 28.82, 28.08, 25.47, 
25.04. 
(E)-tert-butyl 7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxo-5,6-dihydropyridin-1(2H)- 
yl)prop-1-enyl)phenoxy)heptanoate (15) 
Step 1: compound 9 (540 mg, 1.3 mmol, 1.0 eq) was dissolved in DCM (12 
mL) followed by addition of oxalyl chloride (0.6 mL, 6.5 mmol, 5.0 eq) and catalytic 
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amount of DMF (two drops). The reaction mixture was stirred at room temperature 
for 1 h after which the solvent was removed under reduced pressure. The residue 
was dissolved in THF (3 mL) and directly used in the next step without purification. 
Step 2: compound 11 (150 mg, 1.6 mmol, 1.2 eq) was dissolved in anhydrous 
THF (5 mL) and n-BuLi (2.5 M in hexane, 0.7 mL, 1.7 mmol, 1.3 eq) was added 
dropwise via syringe at -78oC. The reaction mixture was stirred for 15 min at the 
same temperature followed by the dropwise addition of the THF solution in the 
first step. TLC showed the completion of the reaction within about 30 min at -78°C. 
Sat. aq. NH4Cl was added to quench this reaction and the resulting solution was 
extracted with ethyl acetate three times. The combined organic phase was 
washed with water and brine, and dried over anhydrous Na2SO4. Flash 
chromatography (Hex/EA, 4:1) purification afforded product as yellow oil (358 mg, 
56%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.66 (d, J=15.6Hz, 1H), 7.39 (d, 
J=15.6Hz, 1H), 6.91-6.94 (m, 1H), 6.77 (s, 2H), 6.02 (m, 1H), 4.02 (t, J=6.6Hz, 
2H), 3.96 (t, J=6.6Hz, 2H), 3.85 (s, 6H), 2.45-2.47 (m, 2H), 2.19 (t, J=7.8Hz, 2H), 
1.70-1.75 (m, 2H), 1.56-1.61(m, 2H), 1.48-1.44 (m, 2H), 1.42 (s, 9H), 1.32-1.37 (m, 
2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.24, 168.90, 165.84, 153.55, 145.49, 
143.94, 139.31, 130.37, 125.83, 120.83, 105.55, 79.90, 73.46, 56.15, 41.63, 
35.56, 29.91, 28.86, 28.10, 25.52, 25.07, 24.79. HRMS (ESI): calcd. for 
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[C27H37NO7∙Na
+], 510.2468; found, 510.2455. 
(E)-tert-butyl 7-(4-(3-(3-chloro-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop- 
1-enyl)-2,6-dimethoxyphenoxy)heptanoate (16) 
Compound 16 was synthesized from compounds 9 (360 mg, 0.9 mmol) 
and 12 (139 mg, 1.1 mmol) following the  procedure described for compound 15, 
except 9 was activated using pivaloyl chloride (0.2 mL, 1.0 mmol) in the presence 
of TEA (0.2 mL, 1.8 mmol) in THF (5 mL) at -10°C. Flash chromatography 
(Hex/EA, 2:1) purification afforded product as colorless oil (150 mg, oil, 33%). 1H 
NMR (600 MHz, CDCl3): δ (ppm) 7.68 (d, J=15.0Hz, 1H), 7.38 (d, J=15.6Hz, 1H), 
7.07 (t, J=4.8Hz, 1H), 6.77 (s, 2H), 4.06 (t, J=6.6Hz, 2H), 3.99 (t, J=6.6Hz, 2H), 
3.85 (s, 6H), 2.53-2.56 (m, 2H), 2.19 (t, J=7.2Hz, 2H), 1.71-1.74 (m, 2H), 
1.57-1.59 (m, 2H), 1.43-1.63 (m, 2H), 1.41 (s, 9H), 1.33-1.36 (m, 2H). 13C NMR 
(125 MHz, CDCl3): δ (ppm) 173.21, 168.50, 161.37, 153.59, 145.12, 141.10, 
139.58, 130.09, 128.20, 119.99, 105.69, 79.89, 73.46, 56.20, 41.77, 35.55, 29.90, 
28.85, 28.09, 25.51, 25.28, 25.05. HRMS (ESI): calcd. for [C27H36NO7Cl∙Na
+], 
544.2078; found, 544.2054. 
(E)-tert-butyl 7-(2,6-dimethoxy-4-(3-(4-methyl-2-oxo-5,6-dihydropyridin- 
1(2H)-yl)-3-oxoprop-1-enyl)phenoxy)heptanoate (17) 
Compound 17 was synthesized from compounds 9 and 13 following the 
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procedure described for compound 16. 9 (141 mg, 0.3 mmol) was activated using 
pivaloyl chloride (0.1 mL, 0.4 mmol, 1.1 eq) in the presence of TEA (0.1 mL, 2.0 
eq) in THF (5 mL) at -10°C. Compound 13 (44 mg, 0.4 mmol) was deprotonated 
by using n-BuLi (2.0 eq) in THF and then reacted with activated 9 to afford product 
17 (24 mg, 23%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.63 (d, J=15.6Hz, 1H), 
7.40 (d, J=15.6Hz, 1H), 6.76 (s, 2H), 5.81 (d, J=1.2Hz, 1H), 4.00 (t, J=6.6Hz, 2H), 
3.96 (t, J=6.6Hz, 2H), 3.84 (s, 6H), 2.37 (d, J=6.6Hz, 2H), 2.19 (t, J=7.2Hz, 2H), 
1.99 (s, 3H), 1.72 (m, 2H), 1.58 (m, 2H), 1.43-1.48 (m, 2H), 1.41 (s, 9H), 1.33-1.36 
(m, 2H).13C NMR (125 MHz, CDCl3): δ (ppm) 173.25, 168.87, 166.09, 157.85, 
153.54, 143.61, 139.21, 130.46, 121.29, 120.97, 105.50, 79.89, 73.44, 56.13, 
41.53, 35.55, 29.90, 29.89, 28.84, 28.09, 25.50, 25.05, 22.97. HRMS (ESI): calcd 
for [C28H40NO7+H]
+, 502.2805; found, 502.2807. 
(E)-tert-butyl 7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxopiperidin-1-yl)prop-1-enyl) 
phenoxy)heptanoate (18) 
Compound 18 was synthesized from compounds 9 and 14 following the 
procedure described for compound 16. Compound 9 (900 mg, 2.2 mmol) was 
activated using pivaloyl chloride (0.4 mL, 2.4 mmol, 1.1 eq) in the presence of 
TEA (0.6 mL, 2.0 eq) in THF (5 mL) at -10°C. Compound 14 (263 mg, 2.7 mmol) 
was deprotonated by using n-BuLi (2.0 eq) in THF (5 mL) and then reacted with 
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activated 9 to afford product 18 (760 mg, 75%). 1H NMR (600 MHz, CDCl3): δ 
(ppm) 7.59 (d, J=15.0Hz, 1H), 7.31 (d, J=15.6Hz, 1H), 6.74 (s, 2H), 3.95 (t, 
J=6.6Hz, 2H), 3.83(s, 6H), 3.76 (t, J=4.8Hz, 2H), 2.57(t, J=6.6Hz, 2H), 2.18 (t, 
J=7.2Hz, 2H), 1.84-1.86 (m, 4H), 1.69-1.72 (m, 2H), 1.55-1.58 (m, 2H), 1.42-1.46 
(m, 2H), 1.40 (s, 9H), 1.31-1.35 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 
173.86, 173.21, 169.59, 153.53, 143.53, 139.23, 130.39, 121.07, 105.48, 79.87, 
73.42, 56.12, 44.60, 35.53, 34.92, 29.88, 28.84, 28.08, 25.50, 25.04, 22.54, 20.60. 
HRMS (ESI): calcd. for [C27H39NO7∙Na
+], 512.2624; found, 512.2625. 
tert-butyl 7-(2,6-dimethoxy-4-(6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl) 
phenoxy)heptanoate (19) 
Compound 19 was synthesized from compounds 10 and 11 following the 
procedure described for compound 16. 10 (1.0 g, 2.6 mmol) was activated using 
pivaloyl chloride (0.5 mL, 2.9 mmol, 1.1 eq) in the presence of TEA (0.7 mL, 2.0 
eq) in THF (5 mL) at -10°C. Compound 11 (304.9 mg, 3.1 mmol) was 
deprotonated by using n-BuLi (2.0 eq) in THF(5 ml) and then reacted with 
activated 10 to afford product 19 (340 mg, 28%). 1H NMR (600 MHz, CDCl3): δ 
(ppm) 6.96-6.99 (m, 1H), 6.85 (s, 2H), 5.98-6.00 (m, 1H), 4.01 (t, J=6.6Hz, 2H), 
3.96 (t, J=6.6Hz, 2H), 3.84 (s, 6H), 2.59-2.61 (m, 2H), 2.22 (t, J=7.8Hz, 2H), 
1.73-1.77 (m, 2H), 1.58-1.63 (m, 2H), 1.45-1.49 (m, 2H), 1.44 (s, 9H), 1.33-1.39 
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(m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.64, 173.22, 165.56, 152.96, 
145.48, 140.82, 130.66, 125.71, 106.24, 79.87, 73.39, 56.18, 43.72, 35.54, 29.91, 
28.84, 28.08, 25.49, 25.05, 24.88. HRMS (ESI): calcd for [C25H36NO7+H]
+, 
462.2492; found, 462.2491. 
tert-butyl 7-(4-(5-chloro-6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl)-2,6- 
dimethoxyphenoxy)heptanoate (20) 
Compound 20 was synthesized from compounds 10 and 12 following the 
procedure described for compound 16. 10 (1.0 g, 2.6 mmol) was activated using 
pivaloyl chloride (0.5 mL, 2.9 mmol, 1.1 eq) in the presence of TEA (0.7 mL, 2.0 
eq) in THF (5 mL) at -10°C. Compound 12 (413 mg, 3.1 mmol) was deprotonated 
by using n-BuLi (1.5 eq) in THF and then reacted with activated 10 to afford 
product 20 (350 mg, 27%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.11 (t, J=4.2Hz, 
1H), 6.83 (s, 2H), 3.99-4.02 (m, 4H), 3.84 (s, 6H), 2.67-2.70 (m, 2H), 2.22 (t, 
J=7.8Hz, 2H), 1.73-1.77 (m, 2H), 1.58-1.63 (m, 2H), 1.46-1.48 (m, 2H), 1.44 (s, 
9H), 1.34-1.39 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.25, 173.15, 
161.18, 153.07, 141.19, 140.88, 130.02, 127.75, 106.28, 79.90, 73.47, 56.26, 
43.90, 35.55, 29.92, 28.84, 28.09, 25.49, 25.42, 25.06. HRMS (ESI): calcd. for 
[C25H34NO7Cl∙Na
+], 518.1922; found, 518.1922. 
(E)-7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxo-5,6-dihydropyridin-1(2H)-yl)prop-1-e
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nyl)phenoxy)heptanoic acid (21) 
Compound 15 (350 mg, 0.7 mmol) was dissolved in a mixture of DCM/TFA 
(10 mL/1 mL) and the reaction mixture was stirred at room temperature for 
overnight. Upon completion shown by TLC, the reaction mixture was diluted with 
DCM and washed with water and brine, dried over anhydrous Na2SO4. 
Evaporation of solvent afforded product compound 21 (yellow oil, 311 mg, 99%) 
which was used in the next step without purification. 
(E)-7-(4-(3-(3-chloro-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-enyl)-2,
6-dimethoxyphenoxy)heptanoic acid (22) 
Compound 22 was synthesized from 16 following the procedure described 
for compound 21. Compound 16 (130 mg, 0.3 mmol) was dissolved in DCM (5 mL) 
followed by the addition of TFA (1 mL) to afford compound 22 (110 mg, 95%). 1H 
NMR (600 MHz, CDCl3): δ (ppm) 7.69 (d, J=15.6Hz, 1H), 7.39 (d, J=15.0Hz, 1H), 
7.08 (t, J=4.8Hz, 1H), 6.78 (s, 2H), 4.07 (t, J=6.6Hz, 2H), 3.98 (t, J=6.6Hz, 2H), 
3.85 (s, 6H), 2.54-2.57 (m, 2H), 2.35 (t, J=7.2Hz, 2H), 1.71-1.76 (m, 2H), 
1.62-1.67 (m, 2H), 1.45-1.50 (m, 2H), 1.36-1.41 (m, 2H). 13C NMR (125 MHz, 
CDCl3): δ (ppm) 179.33, 168.59, 161.41, 153.57, 145.19, 141.15, 139.51, 130.12, 
128.19, 119.98, 105.70, 73.38, 56.20, 41.79, 35.85, 29.84, 28.78, 25.44, 25.29, 
24.61. 
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7-(2,6-dimethoxy-4-(6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)h
eptanoic acid (23) 
Compound 23 was synthesized from 19 following the procedure described 
for compound 21. Compound 19 (340 mg, 0.7 mmol) was dissolved in DCM (10 
mL) followed by the addition of TFA (2 mL) to afford compound 23 (242 mg, 81%). 
1H NMR (600 MHz, CDCl3): δ (ppm) 9.32 (s, 1H), 6.99-7.02 (m, 1H), 6.84 (s, 2H), 
6.00-6.03 (m, 1H), 4.03 (t, J=6.6Hz, 2H), 3.97 (t, J=6.6Hz, 2H), 3.84 (s, 6H), 
2.60-2.63 (m, 2H), 2.36 (t, J=7.2Hz, 2H), 1.73-1.77 (m, 2H), 1.63-1.68 (m, 2H), 
1.46-1.51 (m, 2H), 1.36-1.41 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 
179.71, 173.77, 166.01, 152.94, 145.99, 140.88, 130.44, 124.97, 106.29, 73.35, 
56.19, 43.83, 33.89, 29.80, 28.69, 25.36, 24.85, 24.59. 
7-(4-(5-chloro-6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl)-2,6-dimethoxyph
enoxy)heptanoic acid (24) 
Compound 24 was synthesized from 20 following the procedure described 
for compound 21. Compound 20 (310 mg, 0.6 mmol) was dissolved in DCM (10 
mL) followed by the addition of TFA (1.5 mL) to afford compound 24 (275 mg, 
99%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.09 (t, J=4.2Hz, 1H), 6.80 (s, 2H), 
4.00 (t, J=6.6Hz, 2H), 3.98 (t, J=6.6Hz, 2H), 3.81 (s, 6H), 2.65-2.68 (m, 2H), 2.35 
(t, J=7.2Hz, 2H), 1.70-1.75 (m, 2H), 1.61-1.66 (m, 2H), 1.43-1.48 (m, 2H), 
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1.34-1.39 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 180.10, 173.35, 161.43, 
153.01, 141.28, 141.04, 129.97, 127.59, 106.29, 73.47, 56.26, 43.98, 33.89, 
29.76, 28.67, 25.37, 25.34, 24.55.    
(E)-7-(2,6-dimethoxy-4-(3-(4-methyl-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxo
prop-1-enyl)phenoxy)heptanoic acid (25) 
Compound 25 was synthesized from 17 following the procedure described 
for compound 21. Compound 17 (136 mg, 0.3 mmol) was dissolved in DCM (10 
mL) followed by the addition of TFA (1.5 mL) to afford compound 25 (120 mg, 
amber oil, 99%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.63 (d, J=15.6Hz, 1H), 7.37 
(d, J=15.6Hz, 1H), 6.77 (s, 2H), 5.84 (s, 1H), 3.96-4.00 (m, 4H), 3.83 (s, 6H), 2.39 
(t, J=6.0Hz, 2H), 2.33 (t, J=7.2Hz, 2H), 2.00 (s, 3H), 1.69-1.74 (m, 2H), 1.61-1.65 
(m, 2H), 1.43-1.48 (m, 2H), 1.34-1.39 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 
(ppm) 179.72, 169.28, 166.85, 159.21, 153.49, 144.23, 139.15, 130.37, 120.78, 
120.71, 105.58, 73.41, 56.09, 41.72, 33.90, 29.85, 29.76, 28.74, 25.40, 24.58, 
23.03. 
(E)-7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxopiperidin-1-yl)prop-1-enyl)phenoxy)h
eptanoic acid (26) 
Compound 26 was synthesized from 18 following the procedure described 
for compound 21. Compound 18 (400 mg, 0.8 mmol) was dissolved in DCM (10 
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mL) followed by the addition of TFA (2.0 mL) to afford compound 26 (354 mg, 
yellow oil, 99%). 1H NMR (600 MHz, CDCl3): δ (ppm) 10.15 (s, 1H), 7.61 (d, 
J=15.6Hz, 1H), 7.31 (d, J=15.6Hz, 1H), 6.76 (s, 2H), 3.97 (t, J=6.6Hz, 2H), 3.84 (s, 
6H), 3.76 (t, J=6.0Hz, 2H), 2.59 (t, J=6.6Hz, 2H), 2.34 (t, J=7.2Hz, 2H), 1.84-1.87 
(m, 4H), 1.70-1.75 (m, 2H), 1.61-1.66 (m, 2H), 1.44-1.49 (m, 2H), 1.35-1.40 (m, 
2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 179.54, 174.14, 169.71, 153.52, 143.71, 
139.20, 130.39, 121.07, 105.51, 73.34, 56.13, 44.68, 34.88, 33.90, 29.82, 28.77, 
25.44, 24.60, 22.52, 20.57. 
(E)-methyl 7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxo-5,6-dihydropyridin-1(2H)-yl) 
prop-1-enyl)phenoxy)heptanoate (27) 
Compound 21 was dissolved in diethyl ether/MeOH (6 mL/0.6 mL) and 
trimethylsilyldiazomethane (2 M in diethyl ether, 0.2 mL, 1.2 eq) was added at 0°C. 
The reaction mixture was stirred at room temperature overnight. Solvent was 
removed under reduced pressure and the residue was re-dissolved in ethyl 
acetate, washed with water and brine, dried over anhydrous Na2SO4. Crude 
product was purified by flash chromatography (Hex/EA, 2:1) to afford 27 (90 mg, 
yellow oil, 64%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.62 (d, J=15.6Hz, 1H), 7.36 
(d, J=15.6Hz, 1H), 6.88-6.90 (m, 1H), 6.75 (s, 2H), 5.98 (m, 1H), 3.98 (t, J=6.6Hz, 
2H), 3.93 (t, J=6.6Hz, 2H), 3.82 (s, 6H), 3.61 (s, 3H), 2.41-2.44 (m, 2H), 2.27 (t, 
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J=7.2Hz, 2H), 1.67-1.72 (m, 2H), 1.58-1.63 (m, 2H), 1.41-1.46 (m, 2H), 1.30-1.35 
(m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 174.20, 168.85, 165.82, 153.53, 
145.53, 143.82, 139.25, 130.38, 125.76, 120.87, 105.51, 73.35, 56.12, 51.42, 
41.61, 33.99, 29.86, 28.86, 25.46, 24.88, 24.77. HRMS (ESI): calcd. for 
[C24H32NO7+H]
+, 446.2179; found, 446. 2188. 
(E)-methyl 7-(4-(3-(3-chloro-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1- 
enyl)-2,6-dimethoxyphenoxy)heptanoate (28) 
Compound 28 was synthesized from 22 following the procedure described 
for compound 27. Compound 22 (70 mg, 0.15 mmol) was reacted with 
trimethylsilyldiazomethane (2M in diethyl ether, 0.13 mL, 1.2 eq) in a mixture of 
diethyl ether and MeOH (5 mL : 0.5 mL) to afford compound 28 (22 mg, colorless 
oil, 31%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.70 (d, J=15.6Hz, 1H), 7.41 (d, 
J=15.6Hz, 1H), 7.09 (t, J=4.2Hz, 1H), 6.80 (s, 2H), 4.09 (t, J=6.0Hz, 2H), 3.99 (t, 
J=6.0Hz, 2H), 3.88 (s, 6H), 3.67 (s, 3H), 2.57 (q, J=6.0Hz, 2H), 2.32 (t, J=7.2Hz, 
2H), 1.73-1.78 (m, 2H), 1.63-1.68 (m, 2H), 1.46-1.51 (m, 2H), 1.35-1.40 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ (ppm) 174.25, 168.51, 161.38, 153.58, 145.11, 
141.11, 139.55, 130.11, 128.20, 120.00, 105.69, 73.40, 56.20, 51.45, 41.78, 34.02, 
29.88, 28.88, 25.47, 25.29, 24.90. HRMS (ESI): calcd. for [C24H31NO7Cl+H]
+, 
480.1789; found, 480.1795. 
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General procedure for compounds 29-34. To a flask were added carboxylic 
acids 21-26 (1.0 eq), THP protected hydroxyl amine (2.5 eq) and condensing 
reagent HBTU (2.0 eq) and filled with argon. DMF and DIPEA (2.0 eq) were added 
via syringe. The reaction mixture was stirred at room temperature overnight and 
was diluted with water, extracted with ethyl acetate three times. The combined 
organic phase was washed with brine, dried over anhydrous Na2SO4. Crude 
products were purified by flash column chromatography (EA/DCM, 1:1) to afford 
compounds 29-34 with yields from 50% to 80%. 
(E)-7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxo-5,6-dihydropyridin-1(2H)-yl)prop-1-e
nyl) phenoxy)-N-hydroxyheptanamide (1-58) 
Compound 29 (100 mg, 0.2 mmol, 1.0 eq) was dissolved in MeOH (10 mL) 
and then TFA (2 mL) was added. The reaction mixture was continued to stir at 
room temperature for 1 h. Solvent was removed under reduced pressure. Crude 
product was purified by flash column chromatography (DCM/MeOH, 20:1) to 
afford product 1-58 (white solid, 57 mg, 67%). 1H NMR (600 MHz, CDCl3): δ (ppm) 
8.77 (br, s 1H), 7.64 (d, J=15.0Hz, 1H), 7.37 (d, J=15.6Hz, 1H), 6.92-6.95 (m, 1H), 
6.77 (s, 2H), 6.02 (d, J=9.6Hz, 1H), 4.02 (t, J=6.6Hz, 2H), 3.97 (t, J=6.6Hz, 2H), 
3.84 (s, 6H), 2.46 (m, 2H), 2.12 (m, 2H), 1.67-1.70 (m, 2H), 1.60-1.63 (m, 2H), 
1.43-1.45 (m, 2H), 1.31-1.34 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 
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171.45, 168.95, 165.92, 153.48, 145.64, 143.85, 139.15, 130.42, 125.75, 120.93, 
105.58, 73.27, 56.17, 41.66, 32.71, 29.72, 28.59, 25.27, 25.16, 24.78. HRMS 
(ESI): calcd. for [C23H31N2O7+H]
+, 447.2131; found, 447.2129. 
(E)-7-(4-(3-(3-chloro-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-enyl)-2,
6-dimethoxyphenoxy)-N-hydroxyheptanamide (3-35) 
Compound 30 (100 mg, 0.2 mmol) was reacted with TFA (0.5 mL) in MeOH 
(10 mL). After removing all the solvent, crude product was purified by flash column 
chromatography (DCM/MeOH, 20:1) to afford compound 3-35 (50 mg, colorless 
oil, 67%). 1H NMR (600 MHz, CDCl3):
 
δ (ppm) 7.69 (d, J=15.6Hz, 1H), 7.39 (d, 
J=15.6Hz, 1H), 7.09 (t, J=4.8Hz, 1H), 6.79 (s, 2H), 4.08 (t, J=6.6Hz, 2H), 3.99 (t, 
J=6.6Hz, 2H), 3.86 (s, 6H), 2.57 (q, J=6.0Hz, 2H), 2.14 (t, J=7.8Hz, 2H), 1.69-1.73 
(m, 2H), 1.62-1.67 (m, 2H), 1.43-1.48 (m, 2H), 1.34-1.37 (m, 2H). 13C NMR (125 
MHz, CDCl3): δ (ppm) 171.55, 168.55, 161.43, 153.50, 145.04, 141.19, 139.39, 
130.17, 128.16, 120.09, 105.73, 73.30, 56.23, 41.81, 32.70, 29.72, 28.57, 25.29, 
25.25, 25.15. HRMS (ESI): calcd. for [C23H30N2O7Cl+H]
+, 481.1742; found, 
481.1734. 
7-(2,6-dimethoxy-4-(6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl)phenoxy)-N
-hydroxyheptanamide (3-31) 
Compound 31 (184 mg, 0.4 mmol) was dissolved in MeOH (10 mL) 
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following addition of TFA (1 mL) at room temperature. After stirring for 1h, solvent 
was removed under reduced vacuum. Crude product was purified by flash column 
chromatography (DCM/MeOH, 20:1) to afford product 3-31 (58.5 mg, colorless oil, 
40%). 1H NMR (600 MHz, CDCl3): δ (ppm) 8.89 (s, 1H), 6.96-6.99 (m, 1H), 6.83 (s, 
2H), 5.99 (d, J=9.6Hz, 1H), 4.04 (t, J=6.6Hz, 2H), 3.95 (t, J=6.6Hz, 2H), 3.82 (s, 
6H), 2.58-2.60 (m, 2H), 2.06 (t, J=7.2Hz, 2H), 1.67-1.71 (m, 2H), 1.57-1.62 (m, 
2H), 1.39-1.44 (m, 2H), 1.28-1.31 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 173.61, 
171.22, 165.93, 152.84, 145.86, 140.73, 130.58, 125.09, 106.28, 73.02, 56.25, 
43.76, 32.53, 29.69, 28.36, 25.10, 25.03, 24.88. HRMS (ESI): calcd for 
[C21H29N2O7+H]
+, 421.1975; found, 421.1975. 
7-(4-(5-chloro-6-oxo-1,2,3,6-tetrahydropyridine-1-carbonyl)-2,6-dimethoxyph
enoxy)-N-hydroxyheptanamide (3-98) 
Compound 3-98 was synthesized by treating 32 (80 mg, 0.2 mmol) with 
TFA (0.4 mL) in MeOH (5 mL) at room temperature. Crude product was purified by 
flash column chromatography (DCM/MeOH, 20:1) to afford pure compound 
(lightly yellow solid, 38 mg, 56%). 1H NMR (600 MHz, CDCl3): δ (ppm) 9.08 (s, 
1H), 7.09 (t, J=4.8Hz, 1H), 6.78 (s, 2H), 3.96-4.00 (m, 4H), 3.80 (s, 6H), 2.65-2.68 
(m, 2H), 2.06 (t, J=6.6Hz, 2H), 1.66-1.70 (m, 2H), 1.57-1.62 (m, 2H), 1.38-1.42 (m, 
2H), 1.26-1.32 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 173.13, 171.51, 
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161.38, 152.99, 141.19, 141.04, 130.02, 127.61, 106.28, 73.24, 56.31, 43.94, 
32.59, 29.71, 28.46, 25.39, 25.21, 25.16. HRMS (ESI): calcd. for 
[C21H28N2O7Cl+H]
+, 455.1590; found, 455.1585. 
(E)-7-(2,6-dimethoxy-4-(3-(4-methyl-2-oxo-5,6-dihydropyridin-1(2H)-yl)-3-oxo
prop-1-enyl)phenoxy)-N-hydroxyheptanamide (35) 
Compound 35 was synthesized by treating 33 (67 mg, 0.1 mmol) with TFA 
(0.5 mL) in MeOH (6.0 mL) at room temperature. Crude product was purified by 
flash column chromatography (DCM/MeOH, 30:1) (lightly yellow solid, 20 mg, 
36%). 1H NMR (600 MHz, CDCl3): δ (ppm) 8.77 (bs, 1H), 7.63 (d, J=15.6Hz, 1H), 
7.39 (d, J=15.0Hz, 1H), 6.77 (s, 2H), 5.82 (s, 1H), 3.99 (t, J=6.0Hz, 2H), 3.97 (t, 
J=6.0Hz, 2H), 3.84 (s, 6H), 2.38 (t, J=5.4Hz, 2H), 2.12 (m, 2H), 2.00 (s, 3H), 
1.68-1.70 (m, 2H), 1.61-1.64 (m, 2H), 1.40-1.46 (m, 2H), 1.30-1.36 (m, 2H). 13C 
NMR (125 MHz, CDCl3): δ (ppm) 171.37, 168.92, 166.18, 158.01, 153.46, 143.55, 
139.06, 130.51, 121.24, 121.05, 105.55, 73.25, 56.16, 41.57, 32.72, 29.91, 29.71, 
28.58, 25.27, 25.16, 22.99. HRMS (ESI): calcd for [C24H33N2O7+H]
+, 461.2288; 
found, 461.2299. 
(E)-7-(2,6-dimethoxy-4-(3-oxo-3-(2-oxopiperidin-1-yl)prop-1-enyl)phenoxy)-N
-hydroxyheptanamide (36) 
Compound 36 was synthesized by treating 34 (70 mg, 0.1 mmol) with TFA 
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(0.4 mL) in MeOH (10 mL) at room temperature. Crude product was purified by 
flash column chromatography (DCM/MeOH, 20:1) (colorless oil, 15 mg, 26%). 1H 
NMR (400 MHz, DMSO-d6): δ (ppm) 10.32 (s,1H), 7.32 (d, J=16.0Hz, 1H), 6.85 (s, 
2H), 6.54 (d, J=15.6Hz, 1H), 3.82 (t, J=6.4Hz, 2H), 3.77 (s, 6H), 3.12-3.17 (m, 2H),  
2.31 (t, J=7.6Hz, 2H), 1.93 (t, J=7.6Hz, 2H), 1.36-1.61 (m, 10H), 1.20-1.28 (m, 
2H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 173.73, 169.57, 165.39, 153.68, 
139.06, 138.21, 130.80, 121.97, 105.33, 72.80, 56.33, 38.63, 33.36, 32.70, 29.94, 
28.99, 28.78, 25.60, 25.54, 22.38. HRMS(ESI): calcd. for [C23H32N2O7+Na]
+, 
471.2107; found, 471.2100. 
2.4. Biological characterization 
In this collaborative project, the following biological characterization of 
newly synthesized compounds was done by our collaborator, Dr.Yubin Ge group. 
Herein, key points of their anti-leukemic activities are listed and noted. 
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Figure 9. Schematic summary of biological activities of 1-58 in AML cells. 
 
2.4.1. Synergy between SAHA and PL 
The synergistic-to-additive anti-leukemic interactions between PL and 
SAHA provide a compelling rationale to construct PL-HDACi chimeric molecules 
against AML cells. 
2.4.2. Anti-AML activities of the PL-HDACi hybrid 1-58 
On the basis of favorable anti-AML interactions between PL and SAHA, we 
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explored a “hybrid drug” approach to discover a single chemical entity possessing 
both HDACi and PL-related activities. The chimeric compound 1-58  triggered 
concentration-dependent apoptotic cell death, as indicated by a significant 
increase of Annexin V-positive cells and cleavage of PARP and caspase-3. EC50s 
of 1-58 mimicked those of the PL and SAHA combination and were significantly 
lower than those of single agents, indicating improved anti-AML potency. 1-58 
was further tested in other AML cell lines representing various disease subtype 
and status, for instance, in pediatric AML cell lines CMS, CMK, and CMY and in 
Ara-C-resistant HL60/ARC and CMK/ARC cells. 1-58 IC50s were sub-micromolar 
for the cell lines tested and were equivalent or substantially lower than combined 
PL and SAHA treatment. In conclusion, 1-58 shows a broad spectrum of anti-AML 
activities regardless of many disease-specific molecular characteristics, such as 
p53 and FLT3-ITD mutational status. 
2.4.3. SAR of 1-58 
Cellular HDACi activities. Designed as multifunctional anticancer agents, 
chimeric molecules were expected to retain HDACi activities. Results show that 
hybrid molecules 1-58, 3-35, 3-31 and 3-98 maintain strong pan-HDACi activity. 
Comparisons between 1-58/3-35 and 3-31/3-98 demonstrated that the absence of 
C7-C8 olefin in 3-31 and 3-98 did not change HDACi efficacy. 27 and 28, which 
61 
 
lack the hydroxamic acid functional group, didn’t affect acetylation of H4 and 
α-tubulin. The cellular HDACi activity of compound 35 with C3-methyl group was 
better than that of compound 36 in which C2-C3 olefin was saturated. Compared 
to 1-58, structural modification of the 5,6-dihydro-2(1H)-pyridinone ring of PL, by 
introducing a C3-methyl group (compound 35) or saturation of C2-C3 olefin 
(compound 36), decreased cellular HDACi activities. On the contrary, C2-Cl 
substitution and elimination of C7-C8 olefin were well tolerated for cellular HDACi 
activities. These results suggested that the PL or partial PL scaffold was an 
acceptable “cap” group to render effective HDACi activities to the chimeric 
molecules. 
Dual-acting mode. First, to clarify the contributions of HDACi and PL 
moieties to the overall anti-AML effects of chimeric molecule 1-58, close structural 
analogues, i.e. compounds 27, 35 and 36, were tested in U937 cells. Hydroxamic 
acid, the ZBG of 1-58, was replaced by a methyl ester in 27 to eliminate HDACi 
activity. On the other hand, compounds 35 and 36 retained the ZBG but the 
electrophilic C2-C3 olefin of PL was blocked by using C3-methyl substituent in 
compound 35 or via hydrogen saturation in compound 36. The 1-58 and 27 pair 
illustrated the contribution of HDAC inhibition to the anti-leukemic activity of the 
hybrid 1-58. Compound 35 or 36 emphasized C2-C3 olefin-provoked PL-like 
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cellular activities, such as GSH depletion and/or protein alkylation. These results 
suggested that the integration of intact HDACi and PL moieties into one chemical 
entity is necessary for the observed superior anti-AML effects, blocking either 
pharmacophore in close structural analogues significantly decreased their 
apoptotic induction activity. Once getting into AML cells, 1-58 may have a dual 
action mode: some drug molecules act as HDAC inhibitors, and others may 
induce PL-like effects. 3-35 was designed as an analogue of 1-58 with a 
C2-chloro substituent and was used to test if the chemical reactivity of the C2-C3 
olefin plays a role in the biological properties of chimeric molecules. The 1-58 and 
3-35 pair demonstrated that introducing an electron-withdrawing group at the C2 
position of PL enhanced the potency of chimeric molecules, which could be 
attributed to the electron-deficiency of C2-C3 olefin that facilitates the conjugation 
with cellular nucleophiles. 3-31 and 3-98 were synthesized as 1-58 and 3-35 
analogues without the C7-C8 double bond. It has been reported that disrupting 
the electrophilicity of the C7-C8 olefin by saturation, steric blockade or cyclization 
into a heterocycle could substantially diminish PL’s cytotoxicity and covalent 
modification of GSH-binding protein21. Interestingly, these modifications did not 
interfere with ROS production and GSH depletion properties as long as an active 
C2-C3 olefin was intact. 3-31/3-98 had weaker cellular HDACi activities in 
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contrast to 1-58/3-35, which is likely attributed to the absence of C7-C8 olefin. 
Interestingly, 3-31 and 3-98 showed similar potency without C7-C8 olefin involved 
whereas much difference with C7-C8 involved. This observation indicates that 
C2-chloro substituent might heavily rely on C7-C8 olefin to enhance the 
cytotoxicity of hybrid compound. 
2.4.4. Cytotoxicity vs. selectivity 
Since both cytotoxicity and selectivity (i.e., sparing non-cancer cells) are 
important for an anticancer compound, we further evaluated PL, SAHA, PL plus 
SAHA, and chimeric compounds 1-58, 3-31, 3-35 and 3-98 in non-cancer cells. 
PL has been shown to be non-toxic to MCF-10A, a non-cancerous breast 
epithelial cell line, at concentrations up to 15 µM in 24 h treatments3, which makes 
it an interesting model for comparison. 1-58 was more selective than PL + SAHA 
and 3-35. Similar to 1-58, 3-31 and 3-98 also showed selectivity. 3-35 was highly 
toxic and barely showed selectivity because 3-35 may efficiently cause cellular 
GSH depletion and trigger massive protein glutathionylation which may be 
responsible for the non-selective toxicity. Since C2 reactivity is tightly linked to 
overall effects of hybrid compound through GSH conjugation, we conducted an 
N-acetyl cysteine (NAC) rescue experiment. The result emphasized the role of 
GSH depletion and/or ROS induction played in the overall apoptotic effects. 
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2.4.5. DNA damage caused by PL, HDACi and their hybrid drug 1-58 
Since both PL160-161 and HDACis (e.g., SAHA150) are able to induce DNA 
damage and inhibit DNA repair mechanisms, we investigated their impact on the 
integrity of DNA in U937 cells by using alkaline comet assay and western blotting 
assay. The results showed that the reduction of Rad51 and CHK1 contributes to 
the observed significant DNA damage induced by SAHA and PL combination and 
hybrid drug 1-58. Rad51 was up-regulated 1.4-fold by PL (2 μM), which could be a 
cellular adaptive reaction to the PL-induced DNA damage. Strikingly, this increase 
was abolished by the combination with SAHA or by the hybrid compound 1-58. 
2.4.6. Apoptotic proteins affected by PL-HDACi 1-58 
The balance between the expression/activity of the pro- and anti-apoptotic 
pathways could ultimately determine the fate of a given cell. Western blotting 
revealed up-regulation of pro-apoptotic Bim (EL isoform, 1.8 fold) and 
down-regulation of anti-apoptotic protein XIAP (to 0.6 fold) by 1-58. Because PL 
itself didn’t change the expression of Bim and XIAP, the observed modulations 
were mainly attributed to the retained HDACi activity of 1-58. PL and SAHA 
combination, as well as SAHA alone, showed similar effects. 
2.5. Chemistry methods 
General Methods for Chemistry. 1H and 13C NMR spectra were obtained 
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using Varian Mercury 600MHz and Advance 300 MHz spectrometers. Chemical 
shifts are reported as δ values in parts per million (ppm) relative to 
tetramethylsilane (TMS) for all recorded NMR spectra. All reagents and solvents 
were obtained commercially from Acros, Aldrich or Fisher and were used without 
purification. Flash column chromatography was performed over 200−300 mesh 
silica gel. High resolution mass spectral data were collected using a LCT Premier 
XE KD128 instrument. All compounds submitted for biological testing were found 
to be >95% pure by analytical HPLC. HPLC analysis of incubations were 
conducted using a Phenomenex (LunaR) C18, 3.5 μm, 100 mm × 3.0 mm column 
on either a Shimadzu UFLC or Agilent 1100 series HPLC instrument. HPLC 
parameters were: 0.1% formic acid (FA) in 10% CH3OH (solvent A); 0.1% FA in 
CH3CN (solvent B); flow rate 0.5 mL/min; gradient, t = 0 min, 10% B; t = 1 min, 10% 
B; t = 18 min, 80% B; t = 20 min, 80% B; t = 21 min, 95% A. 
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CHAPTER 3 DESIGN, SYNTHESIS, AND BIOLOGICAL CHARACTERIZATION 
OF HYDROXAMIC HDACi PRODRUGS AS ANTI-AML AGENTS 
3.1. Rationale 
 
Scheme 2. Activation mechanism and structure of Prodrugs. a) The design of 
arylboronic acid-masked hydroxamic acid prodrug and the mechanism of 
activation, exemplified using SAHA and Q-582. b) Chemical structures of HDACi 
1-58, prodrug Q-523, and Q-582 derivative 5-33. 
 
Acute myeloid leukemia (AML) remains a challenging disease, overall 
5-year survival is less than 5% in patients over the age of 65167. AML is frequently 
characterized by epigenetic deregulation. Histone deacetylase inhibitors (HDACis) 
target aberrant epigenetic modifications of cancer and have been studied as an 
attractive “targeted” drug class for AML treatment168. Although very promising in 
preclinical models, HDACis as monotherapy only resulted in modest156 or poor169 
clinical activities in AML trials. Multiple factors, such as undesired cardiovascular 
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and gastrointestinal toxicity170, fast elimination, and poor tissue penetration 
caused by metabolic labile and high polar hydroxamic acid zinc binding group 
(ZBG)171, hindered the clinical use of HDACi in AML and other cancer indications. 
To overcome these shortcomings, several prodrug approaches, such as 
carbamate171a, 172- and quinone171b-protected hydroxamic acid prodrugs have 
been proposed with aims to increase metabolic stability and membrane 
permeability of hydroxamic acid-based drugs171a. 
3.2. Design and synthesis of hydroxamic acid HDACi prodrugs 
 
Scheme 3. Synthetic route of prodrugs. Reagents and conditions: (a) PPh3, 
DEAD, THF, 82%; (b) Methylhydrazine, THF, 0°C, 77%; (c) 1. HBTU, DIPEA, THF; 
2. NaIO4, NH4OAc, acetone/H2O (1:1); 57% for Q-523, 60% for Q-582; 75% for 
5-33; (d) Aniline, BOP, DIPEA, DCM, 70%; (e) LiOH, THF/H2O (1:1), 80%; (f) 
(BOC)2O, Et3N, 95%; (g) Bis(pinacolato)diboron, AcOK, Pd(dppf)Cl2, 1,4-dioxane, 
80°C, 80%; (h) Trifluoroacetic acid, DCM, 91%. 
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Herein, we designed a novel HDACi prodrug class by masking the 
hydroxamic acid ZBG with hydrogen peroxide (H2O2)/peroxynitrite 
(PNT)-sensitive, self-immolative aryl boronic acid promoiety. The chemical 
reactions between aromatic boronate/boronic acid and H2O2 (a reactive oxygen 
species, ROS)173 or PNT (a reactive nitrogen species, RNS)174 are specific and 
bioorthogonal and give phenol as the major product. Via 1,6-elimination, the 
phenol intermediate is expected to release free hydroxamic acid and a short-lived 
quinone methide which can be further quenched by H2O or cellular thiols 
(Scheme 2a). In this study, two HDACis, SAHA (vorinostat), an FDA-approved 
drug to treat cutaneous T cell lymphoma175 and 1-58, a piperlongumine-HDACi 
hybrid molecule with potent anti-AML activity30, were converted to prodrugs Q-582 
and Q-523, respectively (Scheme 2a and 2b). Boronic acid instead of boronic 
acid ester was used as promoiety to improve water solubility of Q-582 and Q-523. 
Besides chemical properties, the design of ROS/RNS-activated HDACi 
prodrugs is also reasoned by abundant endogenous ROS/RNS sources in AML 
cells and in disease-relevant microenvironments. Due to malfunctioned redox 
homeostasis pathways, e.g., mitochondrial DNA mutation-induced electron 
transfer chain alteration, FLT3-ITD-caused NADPH oxidase (NOX) upregulation 
and the elevated xanthine oxidoreductase activity65, AML blasts display higher 
69 
 
levels of ROS compared to normal leukocytes176. PNT is formed from the reaction 
of nitric oxide (NO) and superoxide (O2
.-) and it reacts with boronic acid up to a 
million-fold faster than H2O2
174, 177
. The occurrence of AML abnormally upregulates 
and activates NOX4 (an O2
.- generating enzyme) and nitric oxide synthase 3 (also 
known as eNOS) in bone marrow (BM) endothelial cells and results in 
overproduction of NO and ROS178. This event could eventually generate higher 
levels of PNT in the AML BM microenvironment. Compared with the healthy tissue, 
the elevated ROS (e.g., H2O2) and PNT could activate boronic acid-based HDACi 
prodrug and release higher levels of cytotoxic HDACi in AML cells and in 
AML-relevant, ROS/RNS-enriched microenvironments. 
Starting from the pinacol ester 41, hydroxylamine 43 was made by 
deprotecting Mitsunobu reaction product 42 with methylhydrazine. Coupling of 43 
with carboxylic acids 4430 and 47179, followed by the treatment of 
NaIO4/NH4OAc
180 gave prodrugs Q-523 and Q-582 respectively (Scheme 3).  To 
study the potential biological effects of aryl boronic acid, we prepared a close 
structural analogue of Q-582, i.e. compound 54 (5-33) which does not release 
HDACi functionality due to replacing oxygen of ZBG with a methylene group. 
Similar to the synthesis of Q-582, 54 (5-33) was made by condensing 47 with 
amine 51. This intermediate was synthesized from 48 via sequential amine 
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protection, palladium-catalyzed borylation and acidic deprotection (Scheme 3). 
3.3. Chemistry 
2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)isoindolin
e-1,3-dione (42) 
4-(Hydroxymethyl)phenylboronic acid pinacol ester (41, 2.8 g, 12.0 
mmol, 1.0 eq) and N-Hydroxyphthalimide (2.34 g, 14.36 mmol, 1.2 eq) were 
dissolved in anhydrous THF (15 mL) and cooled in ice bath. A mixture of 
DIAD (2.9 g, 14.4 mmol, 1.2 eq) and PPh3 (3.76 g, 14.4 mmol, 1.2 eq) in 
anhydrous THF (15 mL) was added dropwise over 15 min. The reaction 
mixture was allowed to gradually warm up to room temperature and stirred 
overnight. Solvent was removed under reduced pressure and diluted with 
DCM. The organic layer was washed with saturated aqueous NaCl and 
dried over anhydrous Na2SO4. After concentration, residue was purified by 
flash chromatography (Hexane/ethyl acetate, 10:1) to afford product (white 
solid, 3.7 g, 82%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.79 (d, J=7.2Hz, 
2H), 7.76-7.78 (m, 2H), 7.69-7.71 (m, 2H), 7.51 (d, J=7.8Hz, 2H), 5.21 (s, 
2H), 1.32 (s, 12H). 13C NMR (125 MHz, CDCl3): δ (ppm) 163.44, 136.51, 
134.91, 134.43, 128.96, 128.81, 123.49, 83.89, 79.61, 77.26, 77.05, 76.84, 
24.87.   
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O-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)hydroxylamin
e (43) 
To a stirred solution of 42 (3.7 g, 9.8 mmol, 1.0 eq) in anhydrous THF 
(10 mL) was added methyhydrazine (500 mg, 10.7 mmol, 1.1 eq) at 0°C. 
The reaction was completed in 30min accompanied by forming white 
precipitate. After filtration through celite, the filtrate was concentrated and 
the residue was purified by flash chromatography (DCM/MeOH, 10:1) to 
afford product (colorless oil, 1.9 g, 77%). 1H NMR (600 MHz, CDCl3): δ 
(ppm) 7.80 (d, J=7.8Hz, 2H), 7.36 (d, J=7.8Hz, 2H), 5.39 (bs, 2H), 4.70 (s, 
2H), 1.33 (s, 12H). 13C NMR (125 MHz, CDCl3): δ (ppm) 140.59, 134.94, 
127.49, 83.79, 77.83, 24.85.  
(E)-(4-(((7-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl
)prop-1-en-1-yl)phenoxy)heptanamido)oxy)methyl)phenyl)boronic 
acid (Q-523) 
To a stirred solution of 44 (156 mg, 0.36 mmol, synthesized as 
previously described 30) were added HBTU (164 mg, 0.43 mmol, 1.2 eq), 
DIPEA (0.13 mL, 0.72 mmol, 2.0 eq) in anhydrous THF (5.0 mL), 43 (98 mg, 
0.40 mmol, 1.1 eq), and the reaction was stirred at room temperature 
overnight. The reaction was quenched with water and diluted with DCM. 
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The organic layer was separated, washed with water and concentrated to 
give a white solid that was directly used for next step without further 
purification. The crude coupling product was mixed with NH4OAc (58.5 mg, 
0.76 mmol, 2.1 eq) and NaIO4 (231 mg, 1.08 mmol, 3.0 eq) in acetone/water 
(1:1, 10 mL) at room temperature and the reaction was stirred overnight. 
The resulting mixture was diluted with DCM and washed with brine. The 
organic fraction was collected and concentrated. The residue was purified 
by flash chromatography (Hexane/DCM/MeOH, 4:4:0.1) to afford product 
(colorless oil, 120 mg, 57%). 1H NMR (600 MHz, CD3OD): δ (ppm) 7.76 (m, 
1H), 7.59-7.61 (m, 2H), 7.35-7.40 (m, 3H), 7.05-7.08 (m, 1H), 6.88 (s, 2H), 
6.00 (d, J=10.2Hz, 1H), 4.84 (s, 2H), 3.98 (t, J=6.6Hz, 2H), 3.95 (t, J=6.6Hz, 
2H), 3.85 (s, 6H), 2.49-2.51 (m, 2H), 2.06 (t, J=7.2Hz, 2H), 1.66-1.70 (m, 
2H), 1.58-1.62 (m, 2H), 1.46-1.49 (m, 2H), 1.28-1.33 (m, 2H). 13C NMR (125 
MHz, CDCl3): δ (ppm) 172.95, 170.59, 167.76, 155.02, 148.36, 144.45, 
140.36, 135.08, 134.70, 132.12, 129.48, 129.37, 125.98, 122.48, 106.71, 
74.38, 56.74, 54.83, 43.05, 33.80, 30.98, 29.81, 26.67, 26.65, 25.79. HRMS 
(ESI): calcd. for [C30H37BN2O9-H]
-, 578.2550; found, 578.2537. 
Methyl 8-oxo-8-(phenylamino)octanoate (46) 
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Intermediate 47 was synthesized through 46 according to literature179 
with modifications. Aniline (1.0 g, 10.8 mmol, 1.1 eq) and suberic acid 
monomethyl ester (45, 1.75 mL, 9.8 mmol, 1.0 eq) were dissolved in DCM 
(20 mL) and cooled in an ice bath. To the above stirred solution, BOP (5.71 
g, 12.9 mmol, 1.2 eq) and DIPEA (2.27 mL, 12.9 mmol, 1.2 eq) were slowly 
added. The reaction was stirred at room temperature overnight. The 
reaction was quenched with water and diluted by adding DCM. The 
resulting organic layer was washed with water, and dried over anhydrous 
Na2SO4. Crude product was purified by flash chromatography 
(Hexane/Ethyl acetate, 1:1) to afford 46 (yellow solid, 1.8 g, 70%). 1H NMR 
(600 MHz, CDCl3): δ (ppm) 7.50 (d, J=7.8Hz, 2H), 7.40 (bs, 1H), 7.29 (t, 
J=7.8Hz, 2H), 7.08 (t, J=7.8Hz, 1H), 3.65 (s, 3H), 2.33 (t, J=7.2Hz, 2H), 
2.30 (t, J=7.2Hz, 2H), 1.69-1.74 (m, 2H), 1.59-1.64 (m, 2H), 1.33-1.38 (m, 
4H). 13C NMR (125 MHz, CDCl3): δ (ppm) 174.29, 171.36, 137.97, 128.95, 
124.14, 119.75, 51.51, 37.55, 33.93, 28.73, 28.70, 25.32, 24.66. 
8-oxo-8-(phenylamino)octanoic acid (47) 
The methyl ester 46 (2.0 g, 7.6 mmol, 1.0 eq) was dissolved in 
THF/H2O (1:1, 20 mL), followed by addition of LiOH (273 mg, 11.4 mmol, 
1.5 eq). The reaction was vigorously stirred at room temperature for 12h. 
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THF was removed under reduced pressure, and pH of the aqueous solution 
was adjusted to 2-3 using HCl (2 M). DCM was added to re-dissolve the 
precipitated white solid. DCM solution was separated and dried over 
anhydrous Na2SO4. The crude product was purified using flash 
chromatography (DCM/MeOH, 40:1) to afford 47 (white solid, 1.5 g, 80%).    
1H NMR (600 MHz, CD3OD): δ (ppm) 7.52 (d, J=7.2Hz, 2H), 7.28 (t, 
J=7.8Hz, 2H), 7.06 (t, J=7.8Hz, 1H), 2.35 (t, J=7.8Hz, 2H), 2.28 (t, J=7.8Hz, 
2H), 1.67-1.70 (m, 2H), 1.60-1.63 (m, 2H), 1.37-1.39 (m, 4H).  
(4-(((8-oxo-8-(phenylamino)octanamido)oxy)methyl)phenyl)boronic 
acid (Q-582) 
A flask was charged with carboxylic acid 47 (200 mg, 0.80 mmol, 1.0 
eq), anhydrous THF (15 mL) and cooled to 0°C in an ice bath. HBTU (365 
mg, 0.96 mmol, 1.2 eq), DIPEA (0.28 mL, 1.60 mmol, 2.0 eq) and 43 (220 
mg, 0.88 mmol, 1.1 eq) were added and reaction mixture was stirred 
overnight. The reaction was quenched with water and diluted with DCM. 
The organic layer was separated, washed with water and concentrated to 
give a white solid that was directly used for next step. The crude product 
(112 mg) was dissolved in acetone/water mixture (1:1, 10 mL), followed by 
the addition of NH4OAc (38 mg, 0.49 mmol) and NaIO4 (148 mg, 0.69 mmol).  
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The reaction mixture was stirred at room temperature overnight. The 
resulting mixture was extracted with DCM and washed with water. The 
crude product was purified using flash chromatography (DCM/ 
Hexane/MeOH, 4:4:0.5) to afford Q-582 (white solid, 190 mg, 60%). 1H 
NMR (ppm) (600 MHz, CD3OD): δ (ppm) 7.75 (d, J=6.6Hz, 1H), 7.60 (d, 
J=7.8Hz, 1H), 7.51 (d, J=7.8Hz, 2H), 7.40 (d, J=7.8Hz, 1H), 7.35 (d, 
J=7.2Hz, 1H), 7.27 (t, J=7.8Hz, 2H), 7.06 (t, J=7.8Hz, 1H), 4.83 (s, 2H), 
2.34 (t, J=7.2Hz, 2H), 2.03 (t, J=7.2Hz, 2H), 1.65-1.69 (m, 2H), 1.57-1.60 (m, 
2H), 1.35-1.36 (m, 2H), 1.27-1.32 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 
(ppm) 174.67, 172.97, 139.98, 135.13, 134.76, 129.86, 129.53, 129.42, 
125.20, 121.33, 78.89, 37.93, 33.75, 29.96, 29.83, 26.78, 26.54. HRMS 
(ESI): calcd. for [C21H27BN2O5-H]
-, 396.1971; found, 396.1973. 
Tert-butyl (4-bromophenethyl)carbamate (49) 
To a stirred solution of 4-bromophenethylamine (48, 5.0 g, 3.87 mmol, 
1.0 eq) in DCM (20 mL) were added Di-tert-butyl dicarbonate (8.2 g, 37.5 
mmol, 1.5 eq) and triethylamine (10.23 mL, 75 mmol, 3.0 eq). The reaction 
was stirred for overnight at room temperature. Upon completion, the 
reaction was diluted with DCM and washed with water. The DCM solution 
was concentrated. The crude product was purified using flash 
76 
 
chromatography (Hexane/Ethyl acetate, 20:1) to afford 49 (white solid, 7.1 g, 
95%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.40 (d, J=8.4Hz, 2H), 7.04 (d, 
J=8.4Hz, 2H), 4.53 (bs, 1H), 3.12-3.34 (m, 2H), 2.74 (t, J=7.2Hz, 2H), 
1.41(s, 9H). 13C NMR (125 MHz, CDCl3): δ (ppm) 155.80, 137.97, 131.60, 
130.55, 120.22, 79.33, 41.57, 35.62, 28.37. 
Tert-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl) 
carbamate (50) 
Intermediate 49 (3.0 g, 10 mmol, 1.0 eq), bis(pinacolato)diboron (5.1 
g, 20 mmol, 2.0 eq) and AcOK (3.92 g, 40 mmol, 4.0 eq) were mixed in 
dioxane (100 mL) in a flask purged with nitrogen. The reaction was stirred at 
80°C overnight. The resulted mixture was diluted with hexane (100 mL), 
filtrated through celite. After concentration, the crude product was purified 
using flash chromatography (Hexane/EA, 10:1) to afford 50 (white solid, 2.8 
g, 80%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.72 (d, J=7.8Hz, 2H), 7.19 (d, 
J=7.8Hz, 2H), 4.52 (bs, 1H), 3.34-3.36 (m, 2H), 2.78 (t, J=7.2Hz, 2H), 1.40 
(s, 9H), 1.32 (s, 12H). 13C NMR (125 MHz, CDCl3): δ (ppm) 155.82, 142.34, 
135.05, 128.24, 83.71, 83.47, 41.61, 36.29, 28.37, 24.99, 24.83. 
2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-amine 
(51) 
77 
 
Intermediate 50 (1.2 g, 3.5 mmol, 1.0 eq) was dissolved in DCM (20 
mL), cooled in an ice bath. TFA (1.32 mL, 17.3 mmol, 5.0 eq) was added. 
The reaction was gradually warmed up to room temperature and was 
complete in about 3h. Solvent was removed and the crude product was 
purified using flash chromatography (DCM/MeOH, 10:1) to afford 51 (white 
solid, 0.78 g, 91%). 1H NMR (600 MHz, CDCl3): δ (ppm) 8.00 (bs, 2H), 7.74 
(d, J=7.8Hz, 2H), 7.18 (d, J=8.4Hz, 2H), 3.13 (t, J=7.2Hz, 2H), 2.96 (t, 
J=7.2Hz, 2H), 1.31 (s, 12H). 13C NMR (125 MHz, CDCl3): δ (ppm) 139.20, 
135.40, 128.01, 83.79, 40.87, 33.72, 24.80. 
(4-(2-(8-oxo-8-(phenylamino)octanamido)ethyl)phenyl)boronic acid (5-33) 
Carboxylic acid 47 (147 mg, 0.59 mmol, 1.0 eq), HBTU (269 mg, 0.71 
mmol, 1.2 eq) and DIPEA (0.21 mL, 1.18 mmol, 2.0 eq) were dissolved in 
anhydrous THF (10 mL), followed by the addition of 51 (160 mg, 0.65 mmol, 
1.1 eq) at 0 °C. The reaction was stirred at room temperature overnight. The 
resulted mixture was diluted with DCM, washed with water and dried over 
anhydrous Na2SO4. The crude coupling product was directly subjected to 
deprotection without further purification. The coupling product (82 mg, 1.0 
eq) was stirred with NH4OAc (26 mg, 0.34 mmol, 2.0 eq) and NaIO4 (109 
mg, 0.51 mmol, 3.0 eq) in acetone/water (1:1, 10 mL) at room temperature 
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overnight. The resulted mixture was diluted with DCM, washed with water 
and dried over anhydrous Na2SO4. The crude product was purified using 
flash chromatography (DCM: Hex: MeOH 4:4:0.5) to afford 5-33 (white solid, 
50 mg, 75%). 1H NMR (600 MHz, CD3OD): δ (ppm) 7.94 (d, J=4.2Hz, 1H), 
7.66 (d, J=7.2Hz, 1H), 7.52 (d, J=7.8Hz, 2H), 7.26 (t, J=7.8Hz, 1H), 7.19 (d, 
J=7.2Hz, 1H), 7.15 (d, J=7.8Hz, 1H), 7.05 (t, J=7.8Hz, 1H), 3.38 (t, J=6.0HZ, 
2H), 2.77-2.78 (m, 2H), 2.33 (t, J=7.8Hz, 2H), 2.12 (t, J=2.12Hz, 2H), 
1.64-1.69 (m, 2H), 1.55-1.57 (m, 2H), 1.33-1.36 (m, 2H), 1.29-1.31 (m, 2H). 
13C NMR (125 MHz, CD3OD): δ (ppm) 176.16, 174.58, 139.84, 135.15, 
134.84, 129.77, 129.18, 129.06, 126.11, 121.25, 41.73, 37.89, 37.04, 36.57, 
29.95, 29.91, 26.86, 26.72. HRMS (ESI): calcd. for [C22H29BN2O4-H]
-, 
394.2178; found, 394.2176. 
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3.4. Biological characterization 
 
Figure 10. Schematic summary of mechanisms of prodrug activation. 
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3.4.1. Prodrug activation by H2O2 or PNT 
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Figure 11. Prodrug Q-582 activation with H2O2 or PNT and SAHA release in 
cell-free incubations. a) Prodrug Q-582 was activated by H2O2. Q-582 (100 µM) 
was incubated with H2O2 in PBS (pH 7.4) at 37°C for 30 min. Aliquots were 
analyzed by HPLC. b) Q-582 (100 µM) time-dependently released SAHA in the 
presence of H2O2 in 4h in PBS (pH 7.4) at 37°C. c) Prodrug Q-582 was activated 
by peroxynitrite. Q-582 (100 µM) was incubated with indicated reagents in PBS 
(pH 7.4) at room temperature for 15 min. Aliquots of the resulted mixture was 
analyzed using HPLC. d) Prodrug Q-582 was activated by peroxynitrite to release 
SAHA. Q-582 (100 µM) was incubated with peroxynitrite produced by 
X/XO/catalase/PAPA-NONOate system in PBS (pH 7.4) at 37oC. Co-injection of 
SAHA with 4 h sample was used to further confirm SAHA release under enzymatic 
incubation conditions. Benzophenone was used as internal standard (IS). X: 
xanthine; XO: xanthine oxidase; Cat.: catalase; PAPA/NO: PAPA-NONOate. 
 
Following the synthesis (Scheme 3), by using SAHA prodrug Q-582 
as model compound, we first investigated if the designed prodrug can be 
activated by H2O2 or PNT in cell-free incubations. Q-582 was incubated with 
H2O2 at various concentrations in PBS buffer (pH 7.4) at 37°C. As revealed 
by HPLC analysis (Figure 11a), Q-582 reacted with H2O2 within 30 min to 
form two new peaks: the retention time of A (8.2 min) was identical to that of 
SAHA, and peak B (12.2 min) was assigned as the phenol intermediate 
since it eventually disappeared within 4 h, and the disappearance was 
accompanied by the increased peak area of SAHA. At a given time point 
(e.g., at 30 min, Figure 11a), the formation of phenol intermediate and 
SAHA were proportional to H2O2 concentration. Q-582 (100 μM) was 
completely converted to SAHA by equivalent (100 μM) or excessive (500 
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μM) H2O2, whereas only half of the Q-582 was consumed by 50 μM of H2O2 
as determined by comparison of the peak area of SAHA with the standard 
sample (Figure 11b). These observations suggest that Q-582 is rapidly 
oxidized by H2O2 in a stoichiometric manner to release SAHA through a 
phenol intermediate. 
Q-582 was also activated by PNT. PNT was generated by a mixture of 
xanthine (X, 200 mM), xanthine oxidase (XO, 10 mU/mL) and NO donor 
PAPA-NONOate (100 μM) as described in the literature174. X and XO produce 
fluxes of superoxide anion which further reacts with NO to form PNT. Even at 
room temperature, Q-582 was completely converted to a phenol intermediate by 
X/XO/PAPA-NONOate within 15 min (Figure 11c). In sharp contrast, 
PAPA-NONOate itself barely induced any change of Q-582, emphasizing the 
specific reaction between boronic acid and PNT. X/XO alone partially consumed 
Q-582 to generate the phenol, and this conversion was abrogated by the addition 
of catalase (100 U/mL), indicating that Q-582 was specifically oxidized by H2O2, a 
disproportionated product of O2
.- yielded from the X/XO system (Figure 11c). The 
addition of catalase also reduced consumption of Q-582 in the 
X/XO/PAPA-NONOate system, suggesting that both H2O2 and PNT were 
generated and were responsible for the oxidation of aryl boronic acid to form the 
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phenol intermediate in X/XO/PAPA-NONOate incubation. Since catalase removes 
H2O2, Q-582 was mainly consumed by PNT in the X/XO/PAPA-NONOate/catalase 
system. Consistent with H2O2 incubations, the X/XO/PAPA-NONOate/catalase 
system converted Q-582 to the phenol intermediate that gradually released SAHA 
in 4 h (Figure 11d). Taken together, we conclude that Q-582 rapidly reacts with 
either H2O2 or PTN to form a phenol intermediate which subsequently turns into 
SAHA in PBS buffer. 
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3.4.2. Intracellular activation of prodrugs 
 
Figure 12. Prodrugs are activated and reduce AML cell viability. a) Prodrugs 
Q-582 and b) Q-523 reduced viability of both U937 and MV4-11 AML cells. c) 5-33 
didn't affect cell growth of MV4-11 cells. d) The chemical structures of QA and the 
potency of QA against MV4-11 cell viability. QA was tested in MV4-11 cells at 
indicated concentrations for 72h. e) SAHA or f) 1-58 was used alone or combined 
with QA in MV4-11 cells. Cells were treated with each compound alone or drug 
combinations at indicated concentrations for 72h. Cell viability was analyzed by 
using MTT assay. Bars represent mean ± SEM. n.s indicates no statistical 
significance, ** indicates P < 0.01, *** indicates P<0.001. QA: 
4-(Chloromethyl)phenyl acetate. 
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Figure 13. Prodrugs Q-582 and Q-523 concentration-dependently increase 
acetylation of histone H4 (Ac-H4) and α-tubulin (Tub) in MV4-11 cells determined 
by Western Blotting. a) MV4-11 cells were treated with Q-582 or Q-523 at 
indicated concentrations for 6 h. The fold changes for the Ac-H4 and Ac-α-Tub 
were determined by densitometry measurements, normalized to GAPDH, and 
then compared to SAHA treatment. One representative blot from three 
experiments is shown. b) 1-58 is less potent than SAHA in inhibiting nuclear 
HDACs. Following the manufacturer's standard protocol, SAHA (1.0 or 2.5 μM) or 
1-58 (1.0 or 2.5 μM) was incubated with HeLa nuclear extract and substrate for 
15min. The reaction was stopped by adding Fluor de Lys○R  developer, and 
fluorescence was measured at Ex/Em=360 nm/ 460nm. The HDACs activity was 
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normalized by vehicle control. Bars represent mean ± SEM. * indicates P< 0.05, ** 
indicates P < 0.01. 
 
We next tested prodrug activation and anti-proliferative activity of Q-582 
and Q-523 in AML cell culture models. Both prodrugs concentration-dependently 
reduced the viability of U937 and MV4-11 cells, with IC50s in sub µM to low µM 
range (Figure 12a and 12b). MV4-11 was more sensitive to prodrug treatments 
than U937 cells, consistent with their sensitivity to parental HDACis SAHA and 
1-5830. Boronic acid is a structural component of several approved (e.g., 
proteasome inhibitor Bortezomib) or clinically tested drugs181. To assess potential 
biological effects of aryl boronic acid in the designed prodrugs, we prepared 5-33 
(Scheme 2b), a close structural analogue of Q-582. Because of the replacement 
of the oxygen of ZBG with a methylene group, 5-33 cannot release HDACi 
functionality. In contrast to Q-582, 5-33 didn't affect the viability of MV4-11 cells at 
concentrations up to 10μM (Figure 12c).  
In addition, since QM is released upon prodrug activation, we also 
investigated the role of QM in overall anti-leukemic activities of Q-582 or Q-523. 
QA (4-(Chloromethyl)phenyl acetate)182 (Figure 12d) and QB 
(4-Chloromethylphenylboronic acid)183,184 were selected because they were 
reported to be activated and converted to QM inside cells. QB, the same 
H2O2/PNT-sensitive promoiety as Q-582 and Q-523, has negligible effect on cell 
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viability even if the concentration was increased up to 50 μM (data are not shown), 
while QA efficiently decreased cell viability with IC50 value (1.13 ± 0.11 μM) 
(Figure 12d). To further clarify, we combined QA with SAHA or 1-58 and tested 
each drug or drug combo in MV4-11 cells. The result (Figure 12e and 12f) shows 
that SAHA/QA combo performed, when QA concentration is less than one or two 
equivalents of SAHA concentration, as nearly same effect as SAHA, suggesting 
the effect of Q-582 on cell viability comes from activated SAHA instead of 
combinatory effect of SAHA and QM, which is also applicable for Q-523. Although 
combinations of QA (up to 500 nM) and SAHA didn’t outperform SAHA alone 
when used in 1:1 ratio to mimic prodrug setting, QA enhanced 1-58's or SAHA’s 
cytotoxicity when its concentration is increased up to 2-4 fold relative to SAHA's, 
or 5-10 fold relative to 1-58's concentration (Figure 12e and 12f), suggesting QM 
may become a positive contributor to the overall cytotoxicity especially when the 
released HDACis are less cytotoxic than QM. In conclusion, 
Q-582/Q-523-induced growth inhibition is solely due to the released SAHA or 1-58, 
respectively. Since acetylation of histones and α-tubulin is negatively regulated by 
nuclear HDACs or by cytosolic HDAC6, respectively, we measured these HDAC 
inhibition markers to further confirm intracellular activation of prodrugs. Both 
Q-582 and Q-523 concentration-dependently increased acetylation of histone H4 
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and α-tubulin within 6h in MV4-11 and U937 cells (Figure 13a). Compared to the 
same standard SAHA, densitometry analyses revealed that the 1-58 (a hybrid 
HDACi) prodrug Q-523 caused more prominent global acetylation than SAHA 
prodrug Q-582 in MV4-11 and U937 cells (Figure 13a). To understand this 
observation, we measured intrinsic HDAC inhibition activity of parental HDACis 
using enzymatic assay against nuclear HDACs extracted from Hela cells. 
Interestingly, 1 μM 1-58 and SAHA treatment resulted in 32% and 65% inhibition, 
respectively (Figure 13b), demonstrating that 1-58 is weaker HDACi than SAHA 
at nuclear HDACi inhibition. Therefore, compared to Q-582, the increased H4 
acetylation induced by Q-523 (Figure 13a) was likely attributed to the higher 
levels of intracellular free HDACi (but not higher intrinsic HDACi activity), 
potentially caused by: 1) increased intracellular prodrug concentration since 
Q-523 is more lipophilic than Q-582 (ClogP 4.73 vs. 3.26); and 2) the presence of 
ROS-inducing piperlongumine functionality3 enhances oxidative stress in AML 
cells, which facilitates prodrug activation. Besides enhanced acetylation of histone 
H4 and α-tubulin, Q-523 was also more potent than Q-582 in inhibiting cell 
proliferation, reflected by the IC50s of the two prodrugs: 0.70 μM vs. 3.07 μM in 
MV4-11 cells and 1.61 μM vs. 6.13 μM in U937 cells. At least two factors, the 
higher intracellular free HDACi concentration and the stronger anti-proliferative 
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activity of 1-58 than SAHA30, may have contributed to the greater anti-leukemic 
activity of Q-523 than Q-582. 
3.4.3. Intracellular activation of prodrug is under the control of redox status 
 
Figure 14. Intracellular activation of prodrug Q-582 is influenced by ROS/RNS 
inducers and scavengers. a) and b) MV4-11 cells were pre-treated with GSH (5 
mM), GSHEE (5 mM), catalase (0.125 mg/mL), SOD (0.05 mg/mL) or the 
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combination of LPS (10 ug/mL) and BSO (2.5 μM), respectively, for 2h, followed 
by Q-582 (2.5 μM) treatment for 72h. Viable cells were measured using MTT 
assay. Bars represent mean ± SEM. *** indicates P < 0.001. c) MV4-11 cells were 
pretreated with catalase (Cat, 0.5 mg/mL), SOD (0.1 mg/mL), LPS (10 ug/mL) and 
BSO (10 μM) for 2h, followed by Q-582 (2.5 μM) treatment for 24h. Acetylation of 
histone H4 and α-tubulin were analyzed using Western Blotting. The fold changes 
for the Ac-H4 and Ac-α-Tub were obtained by using densitometry measurements, 
normalized to GAPDH, and then compared to Q-582 treatment. One 
representative blot from three experiments is shown. d) Q-582 (100 μM) was 
incubated with GSH (5 mM) in PBS (pH 7.4) at 37 ℃ for 24 h, 48 h and 72 h. The 
reaction was monitored using HPLC. Benzophenone served as the internal 
standard (IS). 
 
We then investigated if prodrug activation is affected by cellular redox 
status. Pretreatment (2 h) with an antioxidant, such as GSH (5 mM), GSH ethyl 
ester (GSHEE, 5 mM) or catalase (0.125 mg/mL), significantly reduced inhibitory 
effect of Q-582 treatment on MV4-11 cell proliferation (Figure 14a). Q-582 was 
stable in GSH co-incubation up to 72h (Figure 14b), suggesting that the rescue of 
MV4-11 cells from Q-582 treatment by GSH or GSHEE was due to scavenging 
intracellular ROS/RNS instead of potential reaction between nucleophilic 
GSH/GSHEE and the electrophilic boron center of Q-582. Catalase exerted the 
rescue function by reducing intracellular H2O2 concentration. On the contrary to 
the antioxidants, H2O2 and/or PNT inducers, such as superoxide dismutase (SOD) 
and a combination of lipopolysaccharide (LPS) and buthionine-(S,R)-sulfoximine 
(BSO), notably enhanced inhibitory effect of Q-582 treatment on the proliferation 
of MV4-11 cells (Figure 14b). SOD catalyses the conversion of O2
.- to H2O2, one 
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of the major sources for prodrug activation. LPS induces iNOS expression and 
BSO depletes cellular GSH, their combination could boost ROS (e.g., H2O2) and 
RNS (e.g., PNT) production and generate oxidative environment favoring 
intracellular prodrug activation. The cell proliferation results (Figure 14a) are well 
correlated with the acetylation levels of histone H4 and α-tubulin in MV4-11 cells 
(Figure 14b): the addition of SOD, the combination of LPS and BSO increased 
whereas adding catalase decreased acetylation of histone H4 and α-tubulin. 
Taken together, our results demonstrate that prodrug activation is under the 
control of cellular redox status: the exogenous ROS/RNS inducers enhance 
whereas antioxidants weaken anti-leukemic activity by influencing prodrug 
activation. 
3.4.4. Prodrug enhances the potency of cytarabine in MV4-11 cells 
 
Figure 15. Prodrugs Q-582 (2.5 µM) and Q-523 (0.5 µM) enhance the effect of 
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cytarabine on the viability of MV4-11 cells. a) MV4-11 cells were treated with 
drugs at indicated concentrations for 72 h, cell viability was measured using MTT 
assay. Bars represent mean ± SEM. *** indicates P < 0.001. b) MV4-11 cells were 
treated with prodrugs and/or cytarabine (0.5 µM) for 24h, expression of cleaved 
caspase-3 and PARP-1 was analyzed by Western Blotting. One representative 
blot from three experiments is shown. 
 
Because of pleiotropic anti-cancer mechanisms, HDACis are a versatile 
component for combinatorial AML treatments to improve overall potency and 
response rate over individual anti-AML agents185. For instance, SAHA was 
combined with chemotherapy drug idarubicin and cytarabine in an AML clinical 
trial186. To explore the possibility of using HDACi prodrugs in combination 
therapies in AML, we investigated the anti-leukemic activities of prodrug Q-582 or 
Q-523 in combination with cytarabine in MV4-11 cells. Both Q-582 (2.5 µM) and 
Q-523 (0.5 µM) significantly enhanced the potency of cytarabine (0.05-0.5 µM) 
(Figure 15a), measured using MTT assay. Consistently, the inhibitory effects on 
proliferation was accompanied by substantially increased PARP-1 and caspase-3 
cleavage induced by the combination compared to individual drug treatment 
(Figure 15b). 
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3.4.5. Selectivity vs toxicity 
 
Figure 16. Q-582 shows selectivity over PCa cancer cells. a) Q-582 significantly 
reduced the viability of PCa C4-2 cells at low micromolar concentrations. b) In 
sharp contrast, Q-582 only slightly affected the cell viability of normal prostatic 
epithelial RWPE-1 cells until its concentration was increased up to 15.0 μM. PCa 
C4-2 and RWPE-1 cells were treated with indicated drugs for 72 h. Cell viability 
was analyzed by using MTT assay. Each experiment was independently repeated 
three times. Bars represent mean ± SEM. *** indicates P<0.001. 
 
Prodrug selectivity was assessed and exemplified by using the model 
compound Q-582. Q-582 didn't affect the viability of human peripheral blood 
mononuclear cells (PBMNCs) when treated with same drug concentrations as 
used in AML MV4-11 cells (This experiment was done my our collaborator Dr. 
Ge's group, data are not shown). In our study, we demonstrated selectivity by 
using PCa C4-2 and normal prostate RWPE-1 cells. As shown in Figure 16a, 
Q-582 reduced C4-2 cell viability with an IC50 value at 4.15±0.393 μM. As a 
prodrug, it was less potent than SAHA (IC50 0.44±0.032 μM). In normal prostate 
cells, Q-582 failed to influence cell viability at doses lower than 10.0 μM, and 
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when the dose was increased to 15.0 μM, Q-582 reduced cell viability by merely 
15% (Figure 16b). Therefore, we conclude that the designed prodrug approach 
(exemplified using Q-582) harbors selectivity to cancer cells (AML or PCa cells) 
over normal cells. 
3.5. Experimental procedures 
3.5.1. Cell lines, antibodies and reagents 
The acute myeloid leukemia (AML) cell lines MV4-11 and U937 were 
obtained from the American Type Culture Collection. MV4-11 and U937 
cells were cultured in RPMI 1640 media supplemented with 10% (v/v) fetal 
bovine serum (Sigma, F8067), L-glutamine (2 mM), penicillin (100 U/mL) 
and streptomycin (100 μg/mL). Cultures were maintained in a humidified 
atmosphere containing 5% CO2/95% air at 37°C. Antibodies used in this 
study are as follows. Anti-acetyl-histone 4 (Cell Signaling Technology, cat# 
2591), anti-acetyl-α-tubulin (Cell Signaling Technology, Cat# 5335), 
anti-GAPDH (Santa Cruz, Cat# Sc-25778), and anti-rabbit IgG, HRP-linked 
antibody (Cell Signaling Technology, cat# 7040). Lipopolysaccharides (LPS, 
L2654), superoxide dismutase (SOD, S5395), glutathione ethyl ester 
(GSHEE, G1404), catalase (C1345), 4-Chloromethylphenyl acetate 
(432881), Xanthine (X4002) and Xanthine Oxidase (X1875) were 
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purchased from Sigma (St. Louis, MO, USA). 4-Chloromethylphenylboronic 
acid (BB-2333) was purchased from Combi-Blocks (CA, USA). Glutathione 
(GSH, BP25211) and hydrogen peroxide were purchased from Fisher (NJ, 
USA). Cytarabine (16069), Buthionine Sulfoximine (BSO, 14484) and 
PAPA-NONOate (82140) were obtained from Cayman Chemical (Ann Arbor, 
Michigan, USA). Piperlongumine (P-004) was from INDOFINE Chemical 
Company (NJ, USA). Vorinostat (SAHA, RV005) was purchased from TSZ 
Chem. LPS, catalase, GSH, GSHEE, BSO and SOD were dissolved in PBS 
(pH 7.4) or in phenol-red free RPMI 1640 medium for cell-free incubations 
or for cell treatment, respectively. All aqueous stock solutions were freshly 
made and used within one day. Stock solutions of HDACis, prodrugs and 
other reagents were prepared in DMSO and stored at -20 °C. HDAC 
fluorimetric assay/drug discovery Kit (BML-AK500) was purchased from 
Enzo Life Sciences and was used by following the manufacturer’s protocols 
and instructions. MTT ((3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium 
bromide, A0357552) was purchased from ACROS (NJ, USA.).   
3.5.2. MTT assay 
U937 or MV4-11 cells were seeded into 96-well plate (6000-8000 cells/well) 
and were treated with the indicated compounds, alone or in combination, for 72 h. 
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The final concentration of DMSO was less than 0.1%. At the end of treatment, the 
MTT ((3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium bromide, 0.5 mg/mL) 
was added to each well, incubated at 37°C for 3 h. Following the incubation, 
supernatant was removed, DMSO (100 µL) was added and the mixture was 
incubated at 37°C for 30 min. Absorbance was read at 570 nM using a microplate 
reader. The wells contain only culture medium and MTT reagent were used as 
blanks for the plate reader. The values of “relative viable cells” were calculated as 
(ODtreatment-ODbackground) /(ODcontrol-ODbackground).  
3.5.3. Western blotting assay 
After drug treatment, U937 or MV4-11 cells were harvested, washed with 
PBS and lysed in RIPA buffer (150mM NaCl, 50mM Tris–HCl, pH 7.4, 5mM EDTA, 
1% NP40, 0.1% SDS) containing 1% PMSF (phenylmethylsulphonyl fluoride, a 
serine protease inhibitor) for 30min over ice. The debris was removed by 
centrifuging at 16,000g for 15min at 4°C. The protein concentration of resulted 
supernatants was determined using Pierce BCA Protein Assay Kit (Thermo Fisher, 
Cat# 23225). 10-20 µg protein in loading buffer was resolved by electrophoresis 
on SDS-PAGE and was electrophoretically transferred onto PVDF 
(polyvinylidenedifluoride) membranes. The 5% nonfat milk was utilized for 
blockade of non-specific binding. Blots were incubated with primary antibody 
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(anti-acetyl-histone 4, anti-acetyl-α-tubulin or anti-GAPDH) overnight at 4°C, 
followed by the incubation of secondary antibody (anti-rabbit IgG) for 1h at room 
temperature. Immunoreactive bands were visualized with ECL (enhanced 
chemiluminescence detection kit) on ImageQuant™ LAS 4000 Imager (GE) as 
described by the manufacturer. Western blots were repeated at least three times, 
and one representative blot is shown. Density of protein bonds were calculated 
and analysed by using imageJ software downloaded from National Institute of 
Health website.  
3.5.4. HPLC analysis 
Enzymatic incubations were quenched by adding equal volume of 
MeOH/ACN mixture (v/v, 1:1), followed by centrifugation at 6,000 rpm. The 
supernatant (10µL) was injected into HPLC for further analysis. HPLC 
analysis was conducted using a Phenomenex Lunna 3µm C18, 3.5 μm, 150 
mm × 3.0 mm column on Agilent 1100 series HPLC instrument. Mobile 
phase were: solvent A, water containing 0.1% formic acid (FA) and 10% (v/v) 
CH3OH; solvent B, 0.1% FA in CH3CN; flow rate 0.5 mL/min; gradient, 
10%B-95%B in 30min. 
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3.5.5. HDAC enzymatic assay 
In vitro HDACs inhibition was measured by using the HDAC 
fluorimetric assay/drug discovery Kit (Enzo Life Sciences, BML-AK500). 
The experiment process follows manufacturer's procedures. Briefly, 
reagents (assay buffer, SAHA or 1-58, HeLa extract) were added orderly, 
and then the Fluor de Lys
○R  substrate was added and mixed thoroughly to 
initiate the reaction according to Table 1 in the protocol. After 15min 
incubation at 37oC, the reaction was stopped by adding the Fluor de Lys
○R  
developer (50 μl). Fluorescence was read at Ex/Em=360 nm/460 nm. 
3.5.6. Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0. Error bars 
represent mean ± standard error of the mean (SEM). The differences between 
sets of data were compared using student’s t-test or one-way ANOVA analysis 
with significant level α=0.05. Asterisks indicate *P < 0.05, **P < 0.01, ***P < 0.001. 
3.5.7. Chemistry methods 
General Methods for Chemistry. 1H and 13C NMR spectra were obtained 
using Varian Mercury 600MHz. Chemical shifts are reported as δ values in parts 
per million (ppm) relative to tetramethylsilane (TMS) for all recorded NMR spectra. 
All reagents and solvents were obtained from Acros, Fisher or Aldrich without 
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further purification. Flash column chromatography was performed over 200−300 
mesh silica gel. High resolution mass spectral data were collected using a LCT 
Premier XE KD128 instrument. All compounds submitted for biological testing 
were found to be >95% pure by analytical HPLC. Purity check was performed via 
HPLC analysis as described in the chapter 2. 
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CHAPTER 4 DESIGN, SYNTHESIS, AND BIOLOGICAL CHARACTERIZATION 
OF DIMERIC PL DERIVATIVES AS ANTI-PCa AGENTS 
4.1. Rationale 
PL's attractive anti-cancer activities heavily rely on PL structural 
uniqueness. PL consists of two α,β-unsaturated carbonyl moieties known as 
"Michael-acceptors", thereby harboring electrophilicity. The functionalities of 
C2-C3 and C7-C8 olefins are associated with GSH conjugation and protein 
glutathionylation, and are determinants of the cellular effects of PL (Figure 3). 
Elevated ROS is the critical player mediating anti-cancer activates of PL, which is 
attributed to C2-C3 olefin functionality21 as introducing chlorine at C2 notably 
enhanced ROS production and cytotoxicty25,26. C7-C8 olefin is responsible for the 
covalent modification of GSH-binding proteins, thereby enhancing PL's 
cytotoxicity21. Because of its anti-cancer activities and the intrinsic relationship 
between electrophilicity and oxidative stress25, PL has been explored as a 
versatile anti-cancer agent applying in the electrophilic prooxidant anti-cancer 
strategy. Additionally, multimeric electrophiles, including dimers of 
melampomagnolide B 187, dimeric catechol188, and PL dimers189, are more 
cytotoxic than the corresponding monomers in cancer cells. Building on the 
diverse anti-cancer activities of PL and the higher anti-cancer potency of 
dimerized or oligomerized electrophiles, we designed and synthesized a class of 
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dimeric PL derivatives (DiPLs) and hypothesized that the extra electrophilic 
moiety of DiPLs may facilitate the recognition of oligomeric cellular targets 
through multivalent interactions190 or the crosslinking of cellular nucleophiles, 
which cannot be achieved by increasing concentration of monomeric PL. We 
envisioned that anti-cancer properties of PL could be significantly enhanced 
through the design of dimeric derivatives. 
4.2. Design and synthesis of DiPLs 
 
Scheme 4. Synthesis of dimeric PL derivatives (DiPLs). Reagents and conditions: 
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(a) (BOC)2O, DMAP, tert-butanol/THF, 70
oC, overnight, 81%; (b) Pd(OAc)2, 
P(O-tolyl)3, DIPEA, 80
oC, anhydrous DMF, overnight, 95%; (c) LiOH, THF/H2O 
(v:v 1:1), 91%; (d) (1) pivaloyl chloride, TEA, anhydrous THF, -20oC; (2) n-BuLi, 
anhydrous THF, -78oC, 21%; (e) TFA, DCM, 90%; (f) TMSCHN2, MeOH/ether (v:v 
1:1), 26%; (g) HBTU, DIPEA, DMF. 
 
To dimerize PL and test the proof of concept, our group firstly synthesized a 
PL dimer (5-17) by multiplying PL's functional groups (Michael acceptors) on the 
benzene ring. This structural modification is supported and inspired by three 
indications: 1) PL-Ben without trimethoxyl groups present shows comparable 
potency at cancer cell growth inhibition and ROS elevation25, suggesting the 
minor involvement of the trimethoxyl groups in PL-related cellular effects. 2) 
PL-HDACi hybrid 1-58 performs synergistic-to-additive anti-leukemic activity30, 
emphasizing feasibility of structural modification at PL benzene ring. 3) The 
anti-cancer activities of PL may be boosted, as accompanied by the increased 
number of Michael acceptors189,191. PL dimer (e.g., 5-17) could significantly 
potentiate interactions with thiol-containing proteins or crosslink cellular 
nucleophiles, thereby effectively killing cancer cells. Moreover, to optimize 
physicochemical properties of the PL dimer 5-17, we increased its hydrophilicity 
by the coupling of carboxylate of 5-17 with nitrogen-containing heterocycles or 
amines. Five such dimeric PL derivatives (DiPLs) were prepared. In our study, 
DiPLs were tested in the CRPC VCaP cells because this cell line is not only 
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resistant to enzalutamide treatment192, but also overexpresses AR and AR-Vs, 
both are key targets for the treatment of CRPC. The positive outcomes from our 
investigation may support the feasibility of PL-based electrophilic prooxidants in 
PCa treatment. In addition, given the favorable cytotoxic profile of the 5-17 
warhead revealed in this study, the DiPL structure can be further modified, 
coupled or merged with other chemical functional groups or nanomaterials to  
further improve potency, tumor localization, and cancer cell selectivity. 
The synthetic route of DiPLs (5-17, 5-37, 5-42, 5-43, 5-44, and 5-45) 
started with a commercially available compound 55, which was converted to a 
acid-labile t-butyl ester 56 by using (BOC)2O and the catalytic amount of DMAP. 
Without disturbing the t-butyl ester group, compound 57 was obtained by reacting 
compound 56 with two equivalents of ethyl acrylate through Heck reaction193. 
Following basic hydrolysis of ethyl ester groups, compound 58 with two carboxylic 
acid groups was obtained and was used for the coupling with δ-valerolactam. To 
prepare compound 59, we used a strong base, n-BuLi, to de-protonate δ-
valerolactam, and the pivaloyl chloride to activate the carboxylic acid groups of 
compound 5830. Next, t-butyl ester group of compound 59 was removed by using 
TFA and the obtained carboxylic acid was esterified with TMS-diazomethane to 
afford the methyl ester 60 (5-17). In order to explore the SAR and optimize 
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drug-like properties of the lead compound 5-17, we also synthesized 62 (5-37), 63 
(5-42), 64 (5-43), 65 (5-44) and 66 (5-45) by coupling 59 with amines 
4-morpholinopiperdine, morpholine, 4-piperidinopiperidine, 
N,N-dimethylpiperidin-4-amine, and dimethylamine, respectively. Synthetic 
intermediates and final products were characterized by using 1H, 13C NMR and 
mass spectrometry. Purity of the final products was checked and confirmed by 
using HPLC analysis. 
4.3. Chemistry 
Tert-butyl 3,5-dibromobenzoate (56) 
The Boc anhydride (2.22 g, 10.2 mmol, 1.5 eq) and compound 55 (1.90 g, 
6.80 mmol, commercially available) were dissolved in a mixture of tert-butyl 
alcohol (7 mL) and THF (2 mL). The reaction was stirred for 10 min at room 
temperature, followed by the addition of DMAP (414.8 mg, 3.4 mmol, 0.5 eq). The 
reaction was heated up to 70oC overnight. Upon completion, the solvent was 
evaporated under reduced pressure and the residue was washed with water, 
extracted with DCM and dried over anhydrous sodium sulfate. The crude product 
was purified by using column chromatography to afford pure product (eluent 
hexane; white solid, 1.84 g, yield 81%). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.01 
(d, J=2.0Hz, 2H), 7.78 (t, J=2.0Hz, 1H), 1.58 (s, 9H). 13C NMR (100 MHz, CDCl3): 
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δ (ppm) 162.97, 137.65, 135.18, 131.191, 122.80, 82.43, 28.06. 
Diethyl 3,3'-(5-(tert-butoxycarbonyl)-1,3-phenylene)(2E,2'E)-diacrylate (57) 
The compound 56 (2.27 g, 6.77 mmol, 1.0 eq) was dissolved in anhydrous 
DMF (6 mL) in a flask filled with argon, followed by the addition of ethyl acrylate 
(1.8 mL, 16.93 mmol, 2.5 eq), Pd(OAc)2 (152.6 mg, 0.68 mmol, 0.1 eq), 
P(O-tolyl)3 (410.9 mg, 1.35 mmol, 0.2 eq) and DIPEA (6 mL). The reaction mixture 
was stirred at 80 oC for overnight. After water wash and DCM extraction, the crude 
product was purified by using silica gel column chromatography (EA/Hexane 1:20) 
to give the product (slightly yellow solid, 2.4 g, yield 95%). 1H NMR (400 MHz, 
CDCl3): δ (ppm) 8.11 (s, 2H), 7.75 (s, 1H), 7.67 (d, J=16.0Hz, 2H), 6.50 (d, 
J=16.6Hz, 2H), 4.25(q, J=7.2Hz, 4H), 1.60 (s, 9H), 1.33 (t, J=14.4Hz, 6H). 13C 
NMR (100 MHz, CDCl3): δ (ppm) 166.44, 164.47, 142.75, 135.34, 133.47, 130.81, 
129.92, 120.22, 81.98, 60.73, 28.13, 14.27. 
(2E,2'E)-3,3'-(5-(tert-butoxycarbonyl)-1,3-phenylene)diacrylic acid (58) 
Compound 57 (494.2 mg, 1.32 mmol, 1.0 eq ) was dissolved in  
THF/water (10 mL, v:v 1:1). To the stirred solution, the LiOH (95.03 mg, 3.96 
mmol, 3.0 eq) water solution was added at room temperature. The reaction 
underwent for overnight. When reaction was completed, as indicated by TLC plate, 
10% citric acid solution was used to acidify the resulting reaction mixture and 
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adjust pH value to 3-4. DCM was added to extract the potential product, followed 
by three times wash with brine and dry over Na2SO4 for 1 hour. Evaporation of 
DCM and purification of flush column chromatography (eluent DCM:MeOH 10:1) 
afford the product. (white solid, 382.0 mg, yield 91%). 1H NMR (400 MHz, C3D6O): 
δ (ppm) 8.31 (s, 1H), 8.22 (d, J=1.2Hz, 2H), 7.77 (d, J=16.0Hz, 2H), 6.75 (d, 
J=16.4Hz, 2H), 1.63 (s, 9H). 13C NMR (100 MHz, C3D6O): δ (ppm) 166.60, 164.21, 
142.91, 135.76, 133.61, 130.65, 130.11, 120.52, 81.35, 27.35. 
Tert-butyl 3,5-bis((E)-3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-en- 
1-yl)benzoate (59) 
Step 1: To a solution of compound 58 (267.1 mg, 0.84 mmol, 1.0 eq) in 
anhydrous THF (5 mL) were slowly added pivaloyl chloride (0.12 mL, 1.85 mmol, 
2.2 eq) and TEA (0.21 mL, 1.56 mmol, 2.5 eq) at -20 oC. After 1h, the resulted 
reaction mixture was ready to use for next step without purification. Step 2: The 
unsaturated valerolactam (256.3 mg, 2.64 mmol, 3.1 eq) was dissolved in 
anhydrous THF (5 mL). Dry ice-ethanol bath was prepared to cool temperature 
down to -78 oC. The n-BuLi (2.5 M in hexane, 1.32 mL, 3.3 mmol, 3.9 eq) was 
added to the lactam THF solution, stirring for 1h. To this stirred solution, the 
mixture prepared in step 1 was added dropwise by using a syringe at -78 oC. After 
4h, saturated NH4Cl was added to quench the reaction and to neutralize 
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excessive n-BuLi. THF was removed and the residue was extracted with DCM. 
The combined organic solution was dried over anhydrous sodium sulfate. The 
concentrated crude product was purified by using silica gel chromatography 
(eluent EA:Hexane 2:1) to afford product (yellow solid, 84.0 mg, yield 21%). 1H 
NMR (400 MHz, CDCl3): δ (ppm) 8.11 (s, 2H), 7.86 (s, 1H), 7.71 (d, J=19.2Hz, 2H), 
7.50 (d, J=27.6Hz, 2H), 6.91-6.70 (m, 2H), 6.03 (d, J=9.6Hz, 2H), 4.02 (t, J=6.8Hz, 
4H), 2.46-2.48 (m, 4H), 1.20 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) 168.61, 
165.67, 164.68, 145.62, 141.55, 135.91, 133.29, 130.90, 130.23, 125.68, 123.66, 
81.75, 41.68, 27.57, 24.76. 
3,5-bis((E)-3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)benzoi
c acid (60) 
To a solution of compound 59 (95.2 mg, 0.2 mmol, 1.0 eq) in DCM (10 mL) 
was slowly added TFA (0.5 mL) at room temperature. The reaction was completed 
in 2 hours and monitored by using TLC. DCM was removed under reduced 
pressure followed by column chromatography (eluent DCM:MeOH 40:1), which 
eventually gave pure product. (white solid, 75.6 mg, yield 90%). 1H NMR (600 
MHz, DMSO-d6): δ (ppm) 8.16 (s, 1H), 8.15 (s, 2H), 7.61 (d, J=15.6Hz, 2H), 7.44 
(d, J=15.6Hz, 2H), 7.08-7.11 (m, 2H), 6.00 (dd, J1=9.6, J2=1.2 Hz, 2H), 3.88 (t, 
J=6.6Hz, 4H), 2.45-2.47 (m, 4H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) 168.49, 
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166.97, 165.93, 18.25, 139.93, 136.44, 132.70, 132.34, 129.61, 125.00, 124.79, 
41.97, 24.75. 
Methyl 3,5-bis((E)-3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl) 
benzoate (5-17) 
The compound 60 (54.6 mg, 0.13 mmol, 1.0 eq) was dissolved in 11 mL 
mixture of MeOH and ether (10:1 v:v), followed by addition of 
trimethylsilyldiazomethane (2 M in diethyl ether, 0.07 mL, 1.2 eq) under ice-cold 
water bath. The reaction underwent at room temperature for overnight and then 
extracted with DCM and dried over sodium sulfate. The column purification 
(eluent EA:Hexane 1:1) affords product. (colorless oil, 14.7 mg, yield 26%). 1H 
NMR (600 MHz, CDCl3): δ (ppm) 8.30 (s, 2H), 7.86 (s, 1H), 7.72 (d, J=15.6Hz, 
2H), 7.52 (d, J=15.0Hz, 2H), 6.93-6.96 (m, 2H), 6.04 (dd, J1=9.6Hz, J2=1.2Hz, 
2H), 4.02 (t, J=6.6Hz, 4H), 3.93 (s, 3H), 2.47-2.50 (m, 4H). 13C NMR (125 MHz, 
DMSO-d6): δ (ppm) 168.57, 166.11, 165.76, 145.74, 141.36, 136.08, 132.03, 
131.45, 130.00, 125.67, 123.80, 52.45, 41.68, 24.77. HRMS (ESI): calcd. for 
[C24H23N2O6+H]
+, 435.1556; found, 435.1541. 
1,1'-((2E,2'E)-3,3'-(5-(4-morpholinopiperidine-1-carbonyl)-1,3-phenylene)bis(
acryloyl))bis(5,6-dihydropyridin-2(1H)-one) (5-37) 
To the solution of compound 60 (100.8 mg, 0.24 mmol, 1.0 eq) dissolved in 
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DMF (5 mL) were added HBTU (110 mg, 0.29 mmol, 1.2 eq), 
4-morpholinopiperdine ( 44.2 mg, 0.26 mmol, 1.1 eq), and DIPEA (0.05 mL, 0.29 
mmol, 1.2 eq) at room temperature. After 4 hours, the resulting reaction was 
extracted with DCM, washed with saturated NaCl solution, and purified by using 
flash chromatography (DCM:MeOH 30:1) to afford 5-37 (colorless oil, 75.6 mg, 
yield 55%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.71 (s, 1H), 7.66 (d, J=16.2Hz, 
2H), 7.55 (s, 2H), 7.47 (d, J=15.6Hz, 2H), 6.92-6.95 (m, 2H), 6.01 (d, J=10.2Hz, 
2H), 4.68-4.70 (m, 1H), 4.02 (t, J=6.6Hz, 4H), 3.70-3.71 (m, 4H), 3.01-3.03 (m, 
1H), 2.81-2.85 (m, 1H), 2.52-2.56 (m, 4H), 2.44-2.47 (m, 6H), 1.95-1.99 (m, 1H), 
1.77-1.79 (m, 1H), 1.54-1.56 (1H), 1.41-1.49 (m, 1H). 13C NMR (125 MHz, CDCl3): 
δ (ppm) 168.86, 168.51, 165.77, 145.82, 141.41, 137.33, 136.14, 129.15, 127.25, 
125.62, 123.73, 67.16, 61.71, 49.69, 46.94, 41.69, 28.94, 24.75. HRMS (ESI): 
calcd. for [C32H36N4O6+H]
+, 573.2713; found, 573.2722. 
1,1'-((2E,2'E)-3,3'-(5-(morpholine-4-carbonyl)-1,3-phenylene)bis(acryloyl))bis
(5,6-dihydropyridin-2(1H)-one) (5-42) 
5-42 was synthesized by following the previously described procedures for 
5-37. The compound 60 (58.8 mg, 0.14 mmol, 1.0 eq) was mixed with HBTU (63.8 
mg, 0.17 mmol, 1.2 eq), morpholine ( 13.4 mg, 0.15 mmol, 1.1 eq) and DIPEA 
( 0.03 mL, 0.17 mmol, 1.2 eq) to eventually afford the pure product 5-42. 
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( colorless oil, 26.0 mg, yield 38%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.72 (s, 
1H), 7.69 (d, J=15.6Hz, 2H), 7.56 (s, 2H), 7.48 (d, J=15.6Hz, 2H), 6.93-6.96 (m, 
2H), 6.01-6.04 (m, 2H), 4.02 (t, J=6.6Hz, 4H), 3.71-3.81 (m, 4H), 3.61-3.63 (m, 
2H), 3.40-3.42 (m, 2H), 2.46-2.49 (m, 4H). 13C NMR (125 MHz, CDCl3): δ (ppm) 
169.07, 168.47, 165.78, 145.82, 141.25, 136.66, 136.27, 129.35, 127.36, 125.63, 
123.87, 66.80, 48.18, 41.65, 24.75. HRMS (ESI): calcd. for [C27H27N3O6+H]
+, 
490.1978; found, 490.1995. 
1,1'-((2E,2'E)-3,3'-(5-([1,4'-bipiperidine]-1'-carbonyl)-1,3-phenylene)bis(acryl
oyl))bis(5,6-dihydropyridin-2(1H)-one) (5-43) 
5-43 was synthesized by following the previously described procedures for 
5-37. The compound 60 (54.6 mg, 0.13 mmol, 1.0 eq) was mixed with HBTU (57.3 
mg, 0.15 mmol, 1.2 eq), 4-piperidinopiperidine ( 24 mg, 0.14 mmol, 1.1 eq) and 
DIPEA ( 0.03 mL, 0.15 mmol, 1.2 eq) to eventually afford the pure product 5-43. 
( white solid, 45.2 mg, yield 61%). 1H NMR (600 MHz, DMSO-d6): δ (ppm) 8.00 (s, 
1H), 7.65 (s, 2H), 7.59 (d, J=16.2Hz, 2H), 7.42 (d, J=15.6Hz, 2H), 7.08-7.11 (m, 
2H), 5.94-5.96 (d, 2H), 4.50-4.53 (m, 1H), 3.88 (t, J=6.6Hz, 4H) 3.55-3.57 (m, 1H), 
3.29-3.36 (m, 2H), 3.00-3.06 (m, 1H), 2.71-2.75 (m, 2H), 2.51-2.68 (m, 1H), 
2.44-2.48 (m, 4H), 1.82-1.89 (m, 1H), 1.68-1.74 (m, 1H), 1.44-1.56 (m, 7H), 
1.38-1.42 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) 168.60, 168.16, 
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165.89, 148.25, 140.18, 138.09, 136.22, 128.65, 127.57, 124.85, 124.77, 62.31, 
55.37, 49.95, 46.92, 42.00, 24.77. HRMS (ESI): calcd. for [C33H38N4O5+H]
+, 
571.2935; found, 571.2920. 
1,1'-((2E,2'E)-3,3'-(5-(4-(dimethylamino)piperidine-1-carbonyl)-1,3-phenylene
)bis(acryloyl))bis(5,6-dihydropyridin-2(1H)-one) (5-44) 
5-44 was synthesized by following the previously described procedures for 
5-37. The compound 60 (54.6 mg, 0.13 mmol, 1.0 eq) was mixed with HBTU (57.3 
mg, 0.15 mmol, 1.2 eq), N,N-dimethylpiperidin-4-amine ( 28.1 mg, 0.14 mmol, 1.1 
eq) and DIPEA ( 0.03 mL, 0.15 mmol, 1.2 eq) to eventually afford the pure product 
5-44. ( white solid, 4.8 mg, yield 7%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.72 (s, 
1H), 7.67 (d, J=15.6Hz, 2H), 7.58 (s, 2H), 7.48 (d, J=15.6Hz, 2H), 6.94-6.97 (m, 
2H), 6.01-6.03 (d, J=9.6Hz, 2H), 4.71-4.78 (m, 1H), 4.02 (t, J=6.6Hz, 4H), 
3.01-3.09 (m, 1H), 2.76-2.84 (m, 1H), 2.47-2.49 (m, 10H), 2.11-2.18 (m, 2H), 
1.98-2.08 (m, 1H), 1.84-1.88 (m, 1H), 1.59-1.62 (m, 1H), 1.49-1.55 (m, 1H). 13C 
NMR (125 MHz, CDCl3): δ (ppm) 168.92, 168.53, 165.77, 145.74, 141.45, 137.30, 
136.15, 129.18, 127.29, 125.68, 123.73, 62.00, 46.97, 41.65, 41.29, 29.69, 24.77. 
HRMS (ESI): calcd. for [C30H34N4O5+H]
+, 531.2607; found, 531.2617. 
N,N-dimethyl-3,5-bis((E)-3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-e
n-1-yl)benzamide (5-45) 
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5-45 was synthesized by following the previously described procedures for 
5-37. The compound 60 (54.6 mg, 0.13 mmol, 1.0 eq) was mixed with HBTU (57.3 
mg, 0.15 mmol, 1.2 eq), Dimethylamine THF solution (0.07 mL, 0.14 mmol, 1.1 eq) 
and DIPEA ( 0.03 mL, 0.15 mmol, 1.2 eq) to eventually afford the pure product 
5-45. (colorless oil, 26.8 mg, yield 46%). 1H NMR (600 MHz, CDCl3): δ (ppm) 7.70 
(s, 1H), 7.68 (d, J=15.6Hz, 2H), 7.58 (s, 2H), 7.48 (d, J=15.6Hz, 2H), 6.92-6.95 (m, 
2H), 6.02 (d, J=10.2Hz, 2H), 4.02 (t, J=6.6Hz, 4H), 3.10 (s, 3H), 2.95 (s, 3H), 
2.45-2.49 (m, 4H). 13C NMR (125 MHz, CDCl3): δ (ppm) 170.30, 168.53, 165.77, 
145.77, 141.53, 137.71, 136.04, 129.15, 127.35, 125.64, 123.60, 41.64, 39.55, 
35.31, 24.76. HRMS (ESI): calcd. for [C25H25N3O5+H]
+, 448.1872; found, 
448.1863. 
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4.4. Biological characterization 
 
Figure 17. Schematic summary of biological activities of DiPLs. 
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4.4.1. Cytotoxicity vs. selectivity 
 
Figure 18. 5-17 selectively reduces viability of PCa cells and is stable in PBS 
buffer. PCa cells were treated with 5-17 a) or PL b) at indicated concentrations for 
72 h. Chemical stability of 5-17 c) or PL d) was monitored by using HPLC. 5-17 
(100 μM) and PL (100 μM) was dissolved in PBS buffer and incubated at 37°C, 
respectively. 3,4,5-Trimethoxybenzoic acid was used as internal standard 1(IS1), 
and benzophenone was used as internal standard 2 (IS2). 
 
Table 3 IC50s of PL and 5-17 against various PCa cell lines 
     Cell linea 
Drugsb 
LNCaP VCaP 22Rv1 PC-3 RWPE-1 
5-17 (nM) 1767±212 557±49.4 589.3±72.2 829.5±165 >2500
c 
PL (nM) 5137±406 4360±178.1 3984±254 5325±690 8260±1291 
a Cells were treated with each drug for 72h, and cell viability was analyzed by 
using MTT assay. 
b Each experiment was independently repeated three times, and data are 
represented as mean ± SEM. 
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c RWPE-1 cell viability was reduced by 29% when treated with 5-17 at maximum 
2500nM for 72h. 
 
To investigate if the newly synthesized 5-17 has selectivity and broad 
anti-PCa spectrum, we used androgen-dependent LNCaP (AR mutant T877A), 
CRPC 22Rv1 (AR mutant H875Y, AR-Vs), CRPC VCaP (WT-AR, AR-Vs), CRPC 
PC-3 (AR negative) and normal prostatic RWPE-1 cells. Cells were treated with 
5-17 or PL for three days, and cell viability was assessed by using MTT assay. As 
shown in Figure 18a and 18b, in agreement with published PL cytotoxic profile3, 
PL efficiently reduced the viability of various PCa cell lines, and PL also 
suppressed the growth of RWPE-1 cells, suggesting its weak selectivity over PCa 
cells (Table 3). 5-17 was shown pan-anti-PCa activities and 3~8 fold more potent 
than PL in reducing the viability PCa cells (Table 3). It is noteworthy that 5-17 
hardly decreased whereas PL reduced viability of RWPE-1 cells by 29% at the 
concentrations where the VCaP cell viability was decreased by 50%. Besides, the 
addition of the second electrophilic moiety didn't increase the instability of 5-17 in 
contrast with PL, as measured in PBS buffer by using HPLC (Figure 18c and 
18d). Therefore, these preliminary results have shown that, compared to PL, 5-17 
is a relatively stable electrophile and has potent and selective anti-PCa activities. 
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4.4.2. DiPL induces ROS accumulation, depletes GSH, and inhibits TrxR in 
VCaP cells 
 
Figure 19. 5-17 increases ROS levels, depletes GSH pool, and inhibits TrxR. a) 
VCaP cells were treated with PL or 5-17 at indicated concentrations for 16h. ROS 
level was measured by using H2DCFDA and normalized by vehicle control. b) 
Intracellular GSH was measured by using monochlorobimane and normalized by 
vehicle control. BSO (500μM) was used as the positive control. c) TrxR enzymatic 
activity was measured by using the TrxR enzymatic kit and normalized by vehicle 
control. VCaP cells were treated with the standard inhibitor solution, PL, or 5-17 
for 3 h, followed by cell lysis and TrxR enzymatic activity measurement. Each 
experiment was independently performed three times, and the bar represents 
mean ± SEM. *P < 0.05, **P < 0.01, ***P< 0.001. 
 
Since PL is reported to elevate ROS levels3, consume GSH pool3, and 
inhibit antioxidant enzyme TrxR19, we tested if 5-17 has similar effects as PL. 
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VCaP cells were tested with PL or 5-17, and intracellular ROS level was 
measured at the 16h time point by using H2DCFDA. As shown in Figure 19a, PL 
and 5-17 could dramatically increase ROS level up to ~1.8 fold at the highest 
concentration when compared to the untreated group. It is noted that only half 
dose of 5-17 was needed to reach the same increased ROS level as PL, which 
suggests that augmented ROS-inducing capacity of 5-17 may stem from the 
doubled Michael acceptors. Besides, PL consumes intracellular GSH pool by 
conjugating GSH at C2 position of C2-C3 olefin3,33,19, so we also investigated if 
5-17 can decrease intracellular GSH content. GSH is involved in scavenging ROS, 
reducing disulfide bond, and detoxifying endo/exogenous electrophile194. As 
shown in Figure 19b, both PL and 5-17 efficiently decreased intracellular GSH in 
6h, and 5-17 was twice as efficient as PL, suggesting that 5-17-induced GSH 
consumption may be attributed to the double electrophilic moieties. Since PL was 
previously identified as a potent inhibitor of TrxR119, we also evaluated 5-17's 
effect on this antioxidant enzyme TrxR. TrxR is a selenocysteine-containing 
protein and known to reduce the thioredoxin (Trx). TrxR inhibition may promote 
NADPH oxidase (NOX) activity, thereby elevating the level of O2
.-
 and H2O2
195. 
Therefore, TrxR has emerged as a promising target for anti-cancer therapy196. In 
our study, 5-17 was also found to inhibit TrxR enzyme activity in a 
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concentration-dependent manner. Inhibition of TrxR by PL was similar in 
magnitude to those of 5-17 at half concentrations (Figure 19c), suggesting that 
the second electrophilic moiety of 5-17 appears not to affect whereas increase the 
odds of binding to TrxR, which is in accordance with the finding that it is the 
electrophilic moiety of PL that binds to TrxR19. Taken together, 5-17, as a result of 
doubling of electrophilic moieties compared to PL, is twice as potent as PL in ROS 
enhancement, GSH consumption and TrxR inhibition. 
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4.4.3. Cytotoxicity of DiPL is influenced by intracellular thiol concentration 
 
Figure 20. Inhibitory potency of PL or 5-17 on cell viability is influenced by 
intracellular thiol concentration. a) VCaP cells were pretreated with indicated 
reagents for 2 h, followed by the treatment of 5-17 (1.0 μM) or PL (5.0 μM). VCaP 
cells were cotreated with PL b) or 5-17 c) for three days following pretreatment 
(16 h) with BSO (100 μM). Cell viability was analyzed by using MTT assay. Each 
experiment was independently performed three times, and the bar represents 
mean ± SEM. n.s indicates no statistical significance. *P < 0.05, **P < 0.01, ***P< 
0.001. 
 
Since PL affects cell viability by modifying thiols and ROS elevation, we 
postulated that free thiol supplement and ROS scavenging may rescue cells from 
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5-17 or PL treatment. To test this hypothesis, we applied free-thiol substances 
(e.g., NAC, GSH, and GSHEE), non-thiol antioxidants vitamin E (e.g., tocopherol 
and trolox), antioxidant enzymes (e.g., catalase) in our study. In agreement with 
the previous findings3,197, cell viability reduction caused by PL could be fully 
reversed by increasing the intracellular free thiol concentration, as observed in 
NAC, GSH, and GSHEE-treated groups (Figure 20a). Vitamin E (tocopherol and 
trolox) and catalase failed to affect cell viability reduction caused by PL, 
suggesting that the cell viability reduction was caused by PL-mediated thiol 
modification rather than ROS24. The similar phenomenon was observed for 5-17 
except that the catalase addition partially rescued 5-17-reduced cell viability 
(Figure 20a). Since there is no evidence supporting the rapid interaction of PL 
with catalase, and catalase has been widely used for studying ROS involvement 
by co-incubating with PL3,25,197,19, we conclude that this partial rescue may be 
attributed to intracellular ROS scavenging by catalase rather than sequestration 
via covalent binding of 5-17 to catalase. Attenuation of cytotoxicity of 5-17 by the 
catalase suggests that H2O2 may play a pronounced role in mediating cytotoxic 
effects of 5-17. The explanation may be relevant to increased inhibitory activity of 
5-17 against TrxR or other enzymes (e.g., GPX1) responsible for removing H2O2. 
On the other hand, since GSH depletion confers cancer cells higher susceptibility 
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of cancer cells to electrophilic compounds such as PL and phenethyl 
isothiocyanate (PEITC)198,199, we applied a specific GSH synthesis inhibitor, BSO, 
to assess the effect of free thiols on PL's or 5-17's overall activity. We pretreated 
VCaP cells with BSO (100μM) for 16h, allowing consumption of GSH pool. 5-17 or 
PL was then added and co-incubated with BSO for three days. The result showed 
that the BSO pretreatment significantly enhanced cytotoxicity of PL or 5-17 
against VCaP cells (Figure 20b and 20c), indicating that GSH depletion makes 
VCaP cells more susceptible to 5-17 or PL treatment. We concluded that 
intracellular free thiols protect cancer cells from being damaged by PL or 5-17, 
and this protection may be mainly manifested in preventing covalent interactions 
of PL or 5-17 with thiol-containing proteins. 
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4.4.4. DiPL decreases AR/AR-V7 protein level in CRPC VCaP cells 
 
Figure 21. PL or 5-17 decreases AR and AR-V7 and increases HO-1and PUMA 
protein levels in VCaP cells. a) PL or 5-17 decreased the protein level of AR and 
AR-V7, meanwhile increased OH-1 in a concentration-dependent manner. b) PL 
or 5-17 increased PUMA protein level. VCaP cells were treated with PL or 5-17 at 
indicated concentrations for 24h, followed by Western Blotting analysis. Each 
experiment was independently performed three times, and one representative blot 
was shown. 
 
Next, we assessed the effect of PL or 5-17 on protein targets or oncogenic 
signaling pathways. AR and AR-Vs are two essential mediators in the progression 
of CRPC74,200, and PL was reported to reduce AR and AR-Vs protein level in 
LNCaP and in PC-3 cells artificially expressing AR-Vs, respectively5. Compared to 
PL, 5-17 more efficiently inhibited PCa cell growth, which inspired us to 
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hypothesize that 5-17 could be used to design more efficient AR/AR-Vs-depleting 
agents. In our study, VCaP cells (p53 heterozygous mutant) were used as the cell 
model to study the AR/AR-Vs depleting effect of 5-17 because of abundant AR 
and AR-Vs expression in VCaP cells. Experimentally, VCaP cells were incubated 
with PL or 5-17 for 24h, AR and AR-V7 protein levels were analyzed by using 
Western Blotting assay. PL could elevate ROS level in many cancer cells and 
directly react with Keap1 and activate Nrf2-HO-1 pathway in breast cancer cells24, 
so HO-1 protein expression was measured in VCaP cells treated with PL or 5-17 
since it was recognized as the marker of oxidative stress201 and the activation of 
Nrf2 pathway202. Additionally, PUMA is a promising drug target and its activation 
leads to mitochondrial-dependent cell apoptosis203. PL was reported to induce 
apoptosis in cancer cells with wild type and null p53 through activation of PUMA3, 
so we also measured the expression level of PUMA. Figure 21a shows that both 
PL or 5-17 downregulated AR and AR-V7 expression in a dose-dependent 
manner and upregulated PUMA (Figure 21b), with 5-17-induced effects being 
more prominent than PL-induced. 5-17 at 0.25 μM was sufficient to induce similar 
AR/AR-V7 depletion as PL at 2.0 μM, correlating with the finding that 5-17 is ~8 
fold more effective in reducing VCaP cell viability than PL. HO-1 expression 
concomitantly upregulated at the doses where AR and AR-V7 notably decreased 
124 
 
(Figure 21a). Since PL was reported to covalently modify Keap1 protein, thereby 
activating Nrf2-HO-1 signaling pathway independently of ROS, these 
observations suggest that 5-17 is a strong AR/AR-V7 depleting agent and may 
function as PL in modulating Keap1 protein and inducing PUMA-dependent cell 
apoptosis independently of ROS. Together with direct ROS elevation (Figure 19a) 
and attenuation of 5-17 cytotoxicity by catalase (Figure 20a), it is plausible that 
ROS participates in pronounced HO-1 upregulation caused by 5-17. In addition, 
5-17 is ~2 fold stronger than PL in ROS induction, GSH depletion, and TrxR 
inhibition, and ~8 fold stronger than PL in AR/AR-V7 protein reduction, HO-1 
induction and cell viability reduction, indicating that doubling electrophilic moieties 
of PL significantly multiplies its anti-PCa activities. 
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4.4.5. 5-17 potency is enhanced by incorporating hydrophilic moieties 
 
Figure 22. 5-43 is more effective in reducing PCa cell viability and downregulating 
AR/AR-Vs. a) RWPE-1 (blue) and VCaP (red) cells were treated with 5-17 and 
5-17 analogs for 72h. Cell viability was analyzed by using MTT assay. b) VCaP 
cells were treated with PL (0.2 μM), 5-17 (0.1 μM), and 5-17 analogs (0.1 μM) for 
24h. AR and AR-V7 were detected by using Western Blotting assay. c) VCaP cells 
were co-treated with 5-43 following 16h pretreatment with BSO (100 μM). Cell 
viability was analyzed by using MTT assay. d) VCaP cells were pretreated with 
BSO (100 μM) for 16h, followed by co-treatment with PL (0.5 μM), 5-17 (0.25 μM), 
and 5-43 (0.25 μM) for 16h. e) NAC treatment fully rescued AR/AR-V7 protein 
loss caused by 5-17. VCaP cells were treated with 5-17 (0.1 μM) following 2h 
pretreatment of NAC (3.0 mM). AR and AR-V7 were detected by using Western 
Blotting assay. Each experiment was independently performed three times, and 
the bar represents mean ± SEM. n.s indicates no statistical significance. *P < 0.05, 
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**P < 0.01, ***P< 0.001. 
 
Next, we refined the 5-17 structure by replacing the methyl ester moiety 
with multiple hydrophilic entities as 5-17 has relatively high CLogP value (4.34, 
calculated by using the Chemdraw software), which may limit its bioavailability 
based on the rational of Lipinski's rule of five, one of which demonstrates 
LogP<5204. To optimize physicochemical properties of 5-17, we selected a series 
of morpholine, piperidine and their derivatives with LogP ranging from -0.6 to +0.6, 
thus producing a class of PL analogs with final CLogP 2~4 (Table 4). Moreover, 
the introduction of these heterocyclic rings or atoms may reveal the tolerability 
and feasibility of structural modifications on the non-electrophilic moiety of 5-17, 
underlying the basis for further modification or incorporation with other chemical 
scaffolds. VCaP cell model was used to evaluate their overall effects on cell 
cytotoxicity and AR/ARV-7 expression. Encouragingly, without sacrificing cancer 
cell selectivity, 5-37, 5-42, and 5-43 were 1.0~1.8 fold more potent than 5-17 in 
reducing VCaP cell viability (Figure 22a), with 5-43 being the most potent analog 
(Table 4). 5-45 was slightly more potent while 5-44 was ~1.9 fold less potent than 
5-17. 5-42 and 5-43 more efficiently decreased AR/AR-V7 protein levels than 5-17 
at the same dose (0.1 μM) (Figure 22b). Given the strongest inhibitory effect of 
5-43 on cell viability and AR/AR-V7 expression, 5-43 was selected to pair with 
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BSO. Since AR and AR-Vs are implicated in progression of CRPC, we further 
tested if 5-17 or 5-17 analogs affect the expression of AR and AR-Vs, and if their 
effects are influenced by intracellular thiol concentration. As expected, GSH 
depletion by BSO pretreatment notably enhanced the potency of 5-43 (Figure 
22c) and accelerated DiPL-induced AR/ARV-7 protein decline (Figure 22d). It is 
noted that 5-43, compared to PL or 5-17, downregulated AR/AR-V7 most when 
combined with BSO (Figure 22d), which correlates with the strongest potency of 
5-43 against PCa cell viability. Figure 22e shows that NAC addition completely 
abrogated 5-17-induced AR and AR-V7 protein reduction. The observation, that 
BSO enhanced whereas NAC reversed 5-17-induced AR/AR-V7 downregulation, 
reveals that thiol-modifying property of 5-17 leads to decreased AR/AR-V7 
expression. In conclusion, PL and DiPLs reduce cell viability through multiple 
mechanisms involving Keap1-Nrf2-HO-1 signaling pathway activation, PUMA 
activation, and AR/AR-V7 downregulation, and these mechanisms stem from PL 
or DiPL-mediated cellular thiols modification. 
Table 4 IC50s of dimeric PL derivatives against VCaP cells. 
 5-17a 5-37a 5-42a 5-43a 5-44a 5-45a 
ClogPb 4.34 2.78 3.00 4.00 2.72 2.84 
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IC50s (nM)
c 
557 
±49.4 
468.5 
±15.6 
464.9 
±60.6 
303 
±31.5 
1042 
±47.1 
518.4 
±21.4 
a  VCaP cells were treated with 5-17 or 5-17 analogs for 72 h. Cell viability was 
measured by using MTT assay. 
b ClogP was calculated by using ChemDraw software. 
c Each experiment was repeated three times. Data are represented as mean ± 
SEM. 
 
4.5. Experimental procedures 
4.5.1. Cell culture 
VCaP, LNCaP, PC-3, 22Rv1, and RWPE-1 cells were purchased from the 
American Type Culture Collection (Manassas, VA, USA). During experiment, PCa 
cell lines were maintained at 37 °C and incubated under humidified 5% CO2/95% 
air in the RPMI media supplemented with 10% (v:v) fetal bovine serum (Sigma, 
F8067), streptomycin (100 μg/mL), penicillin (100 U/mL), and L-glutamine (2 mM). 
RWPE-1 cells were cultured in serum-free Keratinocyte-SFM medium 
supplemented with L-glutamine, EGF (0.005μg/mL) and BPE (0.05mg/mL). 
(Thermo Fisher, Cat# 17005-042). 
4.5.2. Cell viability 
PCa cells were seeded into 96-well plates with 6000-12000 cells in each 
well. The phenol-red free RPMI 1640 medium was supplemented with 10% fetal 
bovine serum and 1% streptomycin. 20,000 RWPE-1 cells were seeded into each 
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well of a 96-well plate and incubated serum-free Keratinocyte-SFM medium. All 
cells were grown at 37°C in a humidified cell incubator with an atmosphere of 5% 
CO2/95% air. After 24h cell attachment, cells were treated with graded 
concentrations of indicated compounds or DMSO vehicle, and the final 
concentration of DMSO in all treated groups is limited to below 0.1%. The fresh 
solution of MTT ((3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) 
agent (ACROS, NJ, USA. Cat#A0357552) was added to each well, and incubated 
with cells for 3h in the 37 °C incubator. Finally, the number of viable cells was 
quantified by using absorbance reading at 570nm. 
4.5.3. Western blotting assay 
PCa cells were harvested, washed with PBS and lysed in RIPA buffer 
(150mM NaCl, 50mM Tris–HCl, pH 7.4, 5mM EDTA, 1% NP40, 0.1% SDS) 
containing 1% PMSF (phenylmethylsulphonyl fluoride) for 30min over ice. The 
Pierce BCA Protein Assay Kit was used for protein concentration of resulting 
supernatants. 40-60ug protein was prepared for SDS gels separation and transfer 
onto PVDF (polyvinylidenedifluoride) membranes. The 5% nonfat milk was 
utilized for blockade of non-specific binding. Blots were incubated with anti-AR 
(Santa Cruz, CA. Cat#sc-816), anti-AR-V7 (Precision, MD. Cat#AG10008), 
anti-HO-1(Cell Signaling, MA. Cat#70081), anti-PUMA (Cell signaling, MA. 
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Cat#4976), and anti-GAPDH (FC-335, Santa Cruze, CA. Cat#E0212.) for 16h, 
followed by conjugation with anti-rabbit IgG (Cell Signaling, MA. Cat#7074) for 1h 
at room temperature. Immunoreactive bands were visualized with ECL (enhanced 
chemiluminescence detection kit, Cat#203-16281, PerkinElmer.Inc, USA). 
Densitometry assay was performed by using imageJ software. 
4.5.4. HPLC analysis 
The indicated compound was dissolved in PBS. The 10µL solution was 
injected into HPLC for analysis. HPLC analysis was conducted using a 
Phenomenex Lunna 3µm C18, 3.5 μm, 150 mm × 3.0 mm column on Agilent 1100 
series HPLC instrument. Mobile phase uses 10% CH3OH (0.1% formic acid, A) 
and CH3CN (0.1% formic acid, B) with flow rate 0.5 mL/min and 10%B-95%B in 
30min gradient. 
4.5.5. Intracellular ROS measurement 
VCaP cells (10,000 cells/well) were seeded into black 96-well plates and 
cultured in 10% FBS RPMI 1640 medium for 48h. After culture medium removal 
and PBS wash (1X), 20μM H2DCFDA (C400, ThermoFisher, USA) dissolved in 2% 
FBS medium was added and incubated with cells for 30 min at 37 oC in the dark. 
Cell groups without H2DCFDA treatment are set as blank. After 30min, cells were 
washed with PBS (1X) to remove H2DCFDA. The fluorescence reading was 
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obtained at Ex/Em=497 nm/527 nm. The reading was set as baseline. Next, cells 
were treated with tested compounds for 16h, followed by reading at Ex/Em=497 
nm/527 m. Fold change= [Reading (sample)- Reading (blank) / Reading 
(baseline)- Reading (blank)] 
4.5.6. Intracellular GSH content measurement 
VCaP cells (10,000 cells/well) were seeded to 96-well plates and cultured 
in 10% FBS RPMI 1640 medium for 24h. BSO (0.5 μM), PL (2.5, 5.0, 10 μM), and 
5-17 (1.25, 2.5, 5.0 μM) were added and incubated with cells for 6h. After medium 
removal and PBS wash (1X), monochlorobimane (100 μM, 69899, Sigma, USA) 
was added and incubated with cells for 30min at 37oC. Following PBS wash (1X) 
and culture medium addition, fluorescence was measured in a plate reader at 
Ex/Em=360 40 nM/460 40 nM. 
4.5.7. TrxR enzymatic assay 
VCaP cells were seeded in 6-well plates with 2.6x106 per well and cultured 
in 10% FBS RPMI 1640 medium for 48h. Cells were treated with PL (1.0, 2.0, 10.0 
μM) and 5-17 (0.5, 1.0, 5.0 μM) for 3h. Following medium removal and PBS wash 
(2X), cells were scraped off, transferred to tubes, centrifuged at 100g for 5 min. 
After removing supernatant, RIPA lysis buffer (50 μL) was added and incubated 
with cells for 30min at 4 oC. Cell lysate was obtained by centrifuging at 10,000g for 
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15min. The Pierce BCA Protein Assay Kit was used for protein concentration of 
resulting supernatants. The amount of enzyme activity was measured and 
calculated according to the manufacture's standard protocol (CS0170, Sigma, 
USA). Briefly, the spectrophotometer at 412nM was set up using an enzymatic 
kinetic program (Delay=120s, interval=10s, the number of reading=6). 180 μL 
working buffer was added to each well of a 96-well plate. Other components, 
including TrxR enzyme, assay buffer (1X), TrxR standard inhibitor solution, and 
DTNB, were added based on the Table 2 of the protocol. 
4.5.8. Statistical analysis 
GraphPad Prism 5.0 was utilized for statistical analysis. Results are 
represented as means ± standard error of the mean (SEM). The differences 
between sets of data were analyzed with student’s t-test or one-way ANOVA 
Bonferroni post test. Significant level was set as α=0.05. Asterisks indicate *P < 
0.05, **P < 0.01, ***P < 0.001. 
4.5.9. Chemistry methods 
General Methods for Chemistry. 1H and 13C NMR spectra were obtained 
using Varian Mercury 600MHz. Chemical shifts are reported as δ values in parts 
per million (ppm) relative to tetramethylsilane (TMS) for all recorded NMR spectra. 
All reagents and solvents were obtained from Acros, Fisher or Aldrich without 
133 
 
further purification. Flash column chromatography was performed over 200−300 
mesh silica gel. High resolution mass spectral data were collected using a LCT 
Premier XE KD128 instrument. All compounds submitted for biological testing 
were found to be >95% pure by analytical HPLC. Purity check was performed via 
HPLC analysis as described in the chapter 2. 
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CHAPTER 5 CONCLUSION 
PL is an electrophilic anti-cancer natural product that selectively kills 
malignant cells over non-malignant cells in preclinical models2-3. Through 
non-covalent or covalent interactions, PL inactivates multiple oncogenic pathways 
(e.g., NF-κB,22 Keap124 and Akt/mTOR6) and suppresses key components of 
cellular antioxidant defense systems (e.g., GSH, GST3 and TrxR205). These 
actions result in pleiotropic anti-cancer effects and in vivo efficacy in animal 
models205. We envisioned that PL is a promising lead for anti-cancer drug 
discovery, and PL derivatives with higher potency and strengthened safety profiles 
represent a new generation of anti-AML/anti-PCa agents that perturb oncogenic 
networks rather than single oncotarget. 
We performed three strategies to enhance anti-AML or anti-PCa selectivity 
and potency of PL derivatives: 1) To design PL-HDACi hybrid drugs (e.g., 
compound 1-58) based on the synergistic anti-AML interactions between PL and 
the HDACi (e.g., SAHA) (Chapter 2)30; 2) Aimed to further improve cancer 
selectivity and drug bioavailability, we designed ROS/PNT-activated hydroxamic 
acid HDACi prodrugs, and used this approach to equip the previously obtained 
PL-HDACis (Chapter 3); 3) To dimerize the PL pharmacophore to generate a 
dimeric PL (DiPL) warhead, as exemplified by a lead compound 5-17 (Chapter 4). 
Both 1-58 and 5-17 are significantly more potent than PL in inhibiting AML or PCa 
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cell proliferation and display broad anti-AML/anti-PCa activities in high-risk and 
treatment-resistant cell lines. 
In Chapter 2, PL was paired with SAHA at ratio 1:1, and this combination 
showed synergism against AML cell lines, which supported our proposal that 
anti-cancer activities of PL can be enhanced by adding HDACi (eg., SAHA) 
through their cooperative and complementary cellular effects. Inspired by this 
finding and the analysis of anti-cancer SAR of PL, we designed PL-HDACi hybrid 
molecule 1-58 by merging PL and SAHA into one single molecule. 1-58 was more 
potent than PL or SAHA alone and their combination at inhibiting AML cell growth. 
To dissect SAR of 1-58, we applied chemistry and biology strategies. Chemically, 
we synthesized 3-98 or 3-35 by introducing an electron-withdrawing chlorine atom 
at the C2 position of PL moiety of 3-31 or 1-58, respectively. 3-98 or 3-31 was 
obtained by eliminating C7-C8 olefins of PL pharmacophore of 3-35 or 1-58, 
respectively. As expected, 3-35 or 3-98 was more potent than 1-58 or 3-31, due to 
the enhanced electrophilicity at the C3 position. 3-35 is the most potent because 
of co-existence of C7-C8 and chlorinated C2-C3 olefins, which also contributes to 
non-selective cytotoxicity toward normal MCF-10A cells. Biologically, we validated 
that both PL and HDACi pharmacophores are necessary to maintain the overall 
anti-leukemic activity of hybrid 1-58. The function of PL pharmacophore is to 
136 
 
interfere with antioxidant defense system. HDACi pharmacophore is responsible 
for downregulating DNA-repair enzymes such as CHK1 and RAD51, increasing 
pro-apoptotic proteins (e.g., Bim), and decreasing anti-apoptotic proteins (e.g., 
XIAP). These effects collectively favor enhanced DNA damage and apoptotic 
death of PL-HDACi hybrid drugs. In summary, we demonstrated the potent 
anti-leukemic activity of PL and HDACi combination, and further designed a 
PL-HDACi hybrid drug class based on the synergistic anti-AML interactions of PL 
and SAHA. Given the higher potency than parental drugs and the selectivity 
between AML and normal cells, the representative hybrid drug 1-58 is a promising 
anti-leukemic lead compound for further optimization. 
The epigenetic deregulation of AML makes HDACi an attractive “targeted” 
drug class for disease treatment. However, the clinical use of hydroxamic 
acid-based HDACis is frequently hindered by undesired cardiovascular and 
gastrointestinal toxicity, as well as fast elimination and poor tissue penetration. 
These challenges prompt us to design HDACi prodrugs and eventually applied 
this methodology to PL-HDACi hybrid drugs. Occurrence of acute myeloid 
leukemia (AML) results in abundant endogenous ROS/RNS sources in AML cells 
and in disease-relevant microenvironments. In Chapter 3, prodrug approach was 
designed accordingly by masking the hydroxamic acid zinc binding group with 
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H2O2/PNT-sensitive, self-immolative aryl boronic acid moiety. Model prodrugs 
Q-582 and Q-523 were derived from FDA-approved SAHA and the previously 
reported PL-HDACi 1-58, respectively. We demonstrated that these prodrugs are 
specifically activated by H2O2 or PNT, leading to intracellular release of active 
HDACi and inhibition of AML cell proliferation. Consistent with the mechanism of 
activation, intracellular activities of prodrugs were increased or reduced by 
ROS/PNT inducers and scavengers, respectively. Q-582 and Q-523 also 
enhanced the potency of chemotherapy drug cytarabine, supporting potentials of 
pairing this prodrug class with conventional chemotherapy drugs. In addition, 
Q-582 displayed promising selectivity as it is well tolerated in normal PBMNCs 
and prostate epithelial RWPE-1 cells compared to AML and PCa cell lines, 
respectively. Given the broad pharmacological effects of HDACi and the critical 
pathological roles of ROS and PNT in various human diseases, including cancer, 
neurodegenerative diseases and metabolic disorders206, H2O2 and PNT-activated 
HDACi prodrugs may be utilized in broader scope other than AML, e.g., in the 
treatment of solid tumors and non-cancer indications. 
Intrinsic electrophilicity is the chemical foundation of PL-induced 
anti-cancer effects. Although “targeted covalent inhibitors”207, a drug class that 
carries thiol-reactive electrophile, are being used for cancer treatment (e.g., 
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EGFR inhibitor afatinib208 and BTK inhibitor ibrutinib209), clinical utilization of 
general electrophiles to target multiple oncogenic pathways is still rare. In this 
area, APR-246 spontaneously converts to electrophilic methylene quinuclidinone 
(MQ) at physiological pH210, and was tested in phase I/IIa blood cancer (including 
AML) and prostate cancer trials. It showed encouraging safety profiles and signs 
of clinical efficacy211. Moreover, APR-246 is currently being assessed in more 
oncology trials either alone or in combination with other drugs (e.g., Dabrafenib, 
NCT03391050). Despite limited success, clinical use of electrophilic compounds 
is concerned due to potential non-selective protein modification, DNA alkylation 
and toxicity to normal cells. From this point of view, the success of multi-target 
electrophiles in cancer treatment is ultimately relied on their selective cytotoxicity 
and whether drug uptake/distribution in tumor tissues can be dramatically 
improved via conjugating with tumor-homing moieties or by drug delivery 
techniques. A recent study shows that highly toxic monomethyl auristatin E (pM 
potency) can be selectively uptaken by prostate cancer cells via conjugating the 
compound to a cancer cell-selective aptamer212. These examples support a 
workflow for discovering PL-based cancer treatments: to discover PL derivatives 
with higher potency and selectivity followed by conjugating the PL-derived 
“warhead” to cancer-targeting moieties. 
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Compared to parental compound, dimerization or oligomerization of an 
electrophile could result in derivatives with higher biological potency. Possible 
explanations include 1) containing more than one copy of electrophilic moiety in 
single molecule; 2) recognizing oligomeric cellular targets through multivalent 
interactions190; 3) crosslinking of cellular nucleophiles. Some of these MOAs 
(mechanism of action), e.g., multivalent binding or crosslinking of cellular targets 
cannot be realized by simply increasing concentration of an electrophilic 
compound. Numerous anti-cancer multimeric electrophiles have been reported, 
such as dimers of melampomagnolide B as potent growth inhibitors of 
hematological and solid tumor cell lines187, dimeric catechol as DNA crosslinking 
agent188, and more specifically, PL oligomers21 or dimers189 are more cytotoxic 
than PL in cancer cells. Inspired by these works, in chapter 4, we designed new 
DiPLs by incorporating two PL pharmacophores onto the phenyl ring of benzoic 
acid at 3 and 5 positions, and the carboxylate group (5-17) is suitable for further 
conjugation to improve water solubility and/or cancer-targeting properties. 
As the first step to explore DiPL-derived anti-AML and anti-PCa agents, a 
small library of DiPLs was synthesized to test if this new scaffold can more 
potently inhibits growth and oncogenic pathways than PL in AML or PCa cells 
without sacrificing selectivity. We also attached water solubility-enhancing polar 
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moieties, such as nitrogen-containing heterocycles to DiPL, to investigate if 
changing physiochemical properties could impact anti-cancer potency and 
selectivity. The anti-AML activities were tested in collaborator’s (Dr. Yubin Ge) lab, 
and the anti-PCa activities was a focus in Chapter 4 of this thesis. AR signaling is 
the primary drug target for PCa treatment. VCaP cell line expresses abundant full 
length AR and AR-V7 and was selected as a cell culture model to test cell growth 
inhibition and AR downregulation properties of DiPLs. DiPL 5-17 more potently 
inhibited VCaP cell growth than PL, reflected by significantly lowered IC50 (557 nM 
vs. 4360 nM). 5-17 also retained cancer cell selectivity, more than 4-fold 
difference were seen between the IC50 values in VCaP and in the non-cancerous 
RWPE1 cells. Under the same experimental conditions, the PL-induced 
differential effects between VCaP and RWPE-1 cells was less than 2-fold. 
Compared to 5-17, DiPLs (e.g., 5-42 and 5-43) more effectively downregulated 
AR and AR-V7 expression as measured using Western blot assays. To correlate 
cellular activity with electrophilicity of DiPLs, we showed that both cell growth 
inhibition and AR/AR-V7 downregulation were significantly enhanced by GSH 
synthesis inhibitor BSO. Apparently, decreased cellular GSH content reduced 
intracellular GSH conjugation, making DiPLs access protein target more easily. 
Overall, our current work identified novel DiPL (e.g., 5-17 and 5-43) scaffolds as 
141 
 
potent and cancer-selective “warhead” that can be used for designing DiPL-based 
cancer-targeting conjugates to further improve safety profiles. 
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Piperlongumine (PL) is an electrophilic anti-cancer natural product. 
Through non-covalent or covalent interactions with cellular targets, PL inactivates 
multiple oncogenic pathways and suppresses key components of cellular 
anti-oxidant/anti-electrophile defense systems. These actions result in pleiotropic 
anticancer effects and are expected to be effective to heterogeneous acute 
myeloid leukemia (AML) and prostate cancer (PCa). We applied two approaches 
to enhance the anticancer potency of PL: 1) To design PL-histone deacetylase 
inhibitor hybrid drugs (PL-HDACis; e.g., 1-58), and 2) To dimerize PL 
pharmacophore to generate a dimeric PL (DiPL) warhead that is suitable for 
further conjugation (e.g., 5-17). Both 1-58 and 5-17 were significantly more potent 
than PL in inhibiting AML or PCa cell proliferation and displayed broad 
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anti-AML/anti-PCa activities in high-risk and treatment-resistant cell lines. In the 
PL-HDACi hybrid drugs, both PL and HDACi structural components are essential 
for cooperatively inducing significant DNA damage and apoptosis in AML cells: PL 
moiety interferes cellular GSH defense, and the HDACi functionality suppresses 
DNA repair and antiapoptotic pathways. The chemical reactivity of PL 
pharmacophore strongly affected potency and selectivity profiles.  In PCa VCaP 
cells, compared to PL, dimeric PL derivatives (DiPLs) more potently inhibited 
VCaP cell growth without sacrificing selectivity, and more effectively 
downregulated expression of androgen receptor (AR) and AR splice variant 7 
(AR-V7). Both growth inhibition and AR/AR-V7 downregulation were significantly 
enhanced by GSH synthesis inhibitor BSO, demonstrating the critical role of 
electrophilicity of DiPL in drug-caused cellular effects. In order to improve disease 
selectivity and drug bioavailability of the newly obtained HDACi hybrid drugs, 
H2O2/peroxynitrite (PNT)-activated hydroxamic acid HDACi prodrugs were 
designed. Model compounds Q-523 and Q-582 were activated in AML cells to 
release cytotoxic HDACis, evidenced by inducing acetylation markers and 
reducing viability of AML cells. Intracellular activation and anti-leukemic activities 
of prodrug were increased or decreased by ROS/PNT inducers and scavengers, 
respectively. Q-582 and Q-523 also enhanced the potency of chemotherapy drug 
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cytarabine in AML cells, supporting the potentials of this prodrug class in 
combinatorial treatment. These prototype hybrid molecules, DiPLs and 
H2O2/PNT-activated HDACi prodrugs may serve as new leads for anticancer drug 
discovery. 
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